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Abstract
Type 2 helper T cells (Th2) are beneficial for orchestrating protective immune responses against
helminths but can also be pathogenic in settings of allergy and asthma. Weak TCR-mediated extracellular
signal-regulated kinase (ERK) signals are thought to promote Th2 differentiation in vitro. However, it was
unclear whether selective enhancement of specific TCR-mediated signal transduction pathways could
suppress Th2 differentiation in vitro and block Th2 inflammation in vivo in a polyclonal setting. The lipid
molecule diacylglycerol (DAG) is the main driver of TCR-mediated ERK activation. Here, we demonstrate
that T cells lacking DAG kinase-ζ (DGKζ), a negative regulator of DAG, display impaired Th2 differentiation
in vitro. Accordingly, mice lacking DGKζ exhibited decreased type 2 airway inflammation and were almost
completely resistant to airway hyperresponsiveness (AHR) in vivo in an OVA-induced mouse model of
allergic asthma. Surprisingly, we found that the mechanisms by which DGKζ protected against airway
inflammation and AHR were separable. Conditional deletion of DGKζ in T cells led to decreased type 2
airway inflammation with no attenuation of AHR. In contrast, conditional deletion of DGKζ in airway
smooth muscle cells led to diminished AHR with no attenuation of airway inflammation. Mechanistically,
T-cell specific enhancement of ERK signaling was sufficient to diminish Th2 differentiation in vitro and
attenuate type 2 airway inflammation with no changes in AHR in vivo. These data demonstrate that
specific enhancement of DAG signaling downstream of the TCR is sufficient to attenuate Th2
differentiation in an ERK-dependent manner. Furthermore, our findings reveal that the inflammatory and
AHR components of asthma are not as interdependent as generally believed.
Additionally, we also demonstrate a novel role for DGKζ in regulating protease allergen-mediated type 2
airway inflammation. We found that global but not hematopoietic-specific ablation of DGKζ was sufficient
to protect from papain-induced airway inflammation. Further analysis revealed that protection from
papain in the absence of DGKζ might be potentially due to an impairment in IL-33 production/release in
response to papain. Collectively, this thesis highlights that DGKζ plays immunomodulatory roles during
Th2 differentiation and in the non-hematopoietic compartments to regulate type 2 immune-mediated
disease.
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ABSTRACT
THE IMMUNOMODULATORY FUNCTIONS OF DIACYLGLYERCOL KINASE ZETA ON
TYPE 2 IMMUNE RESPONSES
Brenal K. Singh
Taku Kambayashi
Type 2 helper T cells (Th2) are beneficial for orchestrating protective immune
responses against helminths but can also be pathogenic in settings of allergy and
asthma. Weak TCR-mediated extracellular signal-regulated kinase (ERK) signals are
thought to promote Th2 differentiation in vitro. However, it was unclear whether selective
enhancement of specific TCR-mediated signal transduction pathways could suppress
Th2 differentiation in vitro and block Th2 inflammation in vivo in a polyclonal setting. The
lipid molecule diacylglycerol (DAG) is the main driver of TCR-mediated ERK activation.
Here, we demonstrate that T cells lacking DAG kinase-ζ (DGKζ), a negative regulator of
DAG, display impaired Th2 differentiation in vitro. Accordingly, mice lacking DGKζ
exhibited decreased type 2 airway inflammation and were almost completely resistant to
airway hyperresponsiveness (AHR) in vivo in an OVA-induced mouse model of allergic
asthma. Surprisingly, we found that the mechanisms by which DGKζ protected against
airway inflammation and AHR were separable. Conditional deletion of DGKζ in T cells
led to decreased type 2 airway inflammation with no attenuation of AHR. In contrast,
conditional deletion of DGKζ in airway smooth muscle cells led to diminished AHR with
no attenuation of airway inflammation. Mechanistically, T-cell specific enhancement of
ERK signaling was sufficient to diminish Th2 differentiation in vitro and attenuate type 2
airway inflammation with no changes in AHR in vivo. These data demonstrate that
specific enhancement of DAG signaling downstream of the TCR is sufficient to attenuate
Th2 differentiation in an ERK-dependent manner. Furthermore, our findings reveal that
vi

the inflammatory and AHR components of asthma are not as interdependent as
generally believed.
Additionally, we also demonstrate a novel role for DGKζ in regulating protease
allergen-mediated type 2 airway inflammation. We found that global but not
hematopoietic-specific ablation of DGKζ was sufficient to protect from papain-induced
airway inflammation. Further analysis revealed that protection from papain in the
absence of DGKζ might be potentially due to an impairment in IL-33 production/release
in response to papain. Collectively, this thesis highlights that DGKζ plays
immunomodulatory roles during Th2 differentiation and in the non-hematopoietic
compartments to regulate type 2 immune-mediated disease.
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CHAPTER 1: INTRODUCTION

Introduction to Th responses
The immune system is critical for protection of the host from microbial exposure
and environmental insults. CD4+ helper T (Th) cells play a key role in orchestrating
immune responses by providing help to B cells and CD8+ cytotoxic T cells and activating
cells of the innate immune system. Recognition of foreign-derived peptides presented on
major histocompatibility complex class II (MHC II) molecules by T cell receptors (TCR)
expressed on naïve, antigen-inexperienced Th cells lead to activation and proliferation of
these cells. Additionally, engagement of the TCR in combination with costimulatory and
cytokine signals initiate differentiation programs that result in the formation of highly
specialized effector Th subsets that secrete distinct sets of cytokines to promote unique
immune functions. These subsets include Th1 cells that produce IFNg to promote
immunity against viruses and intracellular bacteria, Th2 cells that produce IL-4, IL-5, and
IL-13 to promote immunity against helminths, Th17 cells that produce IL-17A, IL-17F,
and IL-22 that are important for protection against extracellular bacteria and fungi, Tfh
cells that produce IL-21 to provide B cell help for the production of high-affinity
antibodies, and iTregs that produce IL-10, IL-35, and TGFb to limit excessive immune
activation. In this manner, Th differentiation allows for the induction of an immune
response that is tailored toward the nature of the encountered threat.
While decades of works have gone into understanding the signals that dictate
differentiation of naïve CD4+ T cells into specific Th lineages in vivo, major gaps still
remain, particularly in the context of Th2 differentiation. The aim of this thesis is to
interrogate the signal requirements for the differentiation of naïve CD4+ T cells into the
1

Th2 lineage. This thesis will examine the roles of the lipid signaling molecule
diacylglycerol (DAG) and the regulation of DAG metabolism by diacylglycerol kinase
zeta (DGKz) in modulating Th2 differentiation and Th2-mediated immune responses.
Furthermore, this thesis will also discuss novel immunomodulatory roles of DGKz in
regulating non-immune responses that are critical for initiating and promoting the
pathological aspects of aberrant type 2 immune responses. Chapter 1 of this thesis will
serve as an introduction into the key molecular signals that instruct Th2 differentiation
and the various roles of DAG and DGKz on immune cell signaling and function.
Signals regulating instruction of Th2 differentiation
Role of cytokine-driven signals in Th2 differentiation
IL-4
A key determinant of the Th differentiation decision is polarizing cues in the form of
cytokines. Interleukin 4 (IL-4) is critical for instructing Th2 differentiation in vitro (1). IL-4
can bind and signal through the type I IL-4 receptor comprised of the IL-4Ra and IL-2Rg
subunits on T cells to induce activation of the Jak1/3-STAT6 pathway (2). Activation of
the STAT6 pathway results in the induction of the transcription factor GATA3, which is
the master regulator of Th2 cell identity, and increased accessibility of the Il4 gene (2).
Consequently, STAT6 KO and GATA3 KO T cells display complete abrogation of Th2
differentiation in the presence of exogenous IL-4 in vitro (3-5). In addition to instructing
the Th2 gene program, IL-4 also represses the induction of alternative gene programs
through the induction of the transcriptional repressor Gfi-1 to suppress the induction of
Th17 and iTreg lineage programs (6).
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In vivo, Th2 differentiation can occur through IL-4-dependent and IL-4independent routes. For IL-4-dependent Th2 differentiation, one of the major questions
in the field has been trying to identify the source of IL-4 for initiating Th2 differentiation.
Many different cell types have been implicated as a relevant source of IL-4, including
type 2 natural killer T cells (NKT2), granulocytes (basophils, eosinophils, and mast cells),
and innate lymphoid cells (ILC2) (7-13). Additionally, conventional naïve CD4+ T cells
can be an early source of IL-4 immediately following TCR activation to initiate
differentiation down the Th2 pathway through an autocrine/paracrine manner (14-16).
Nevertheless, mice lacking IL-4, IL-4Ra, or STAT6 display relatively normal generation
of Th2 cells in response to Nippostrongylus brasiliensis and Trichuris muris, suggesting
that the IL-4-independent route for Th2 differentiation is relevant in certain infection
models (17). However, the factors that regulate IL-4-independent Th2 differentiation are
not completely understood.
IL-2
Interleukin 2 (IL-2) is essential for differentiation of naïve CD4+ T cells into the Th2
lineage. Neutralization of IL-2 blocks Th2 differentiation without affecting T cell
proliferation, suggesting that IL-2 promotes Th2 differentiation independently of the
canonical role of IL-2 in T cell proliferation (1, 3). Indeed, IL-2 maintains chromatin
accessibility of the DNase I hypersensitive sites II (HSII) and III (HSIII) in the second
intron of the Il4 locus through a STAT5-dependent manner (3). In accordance, IL-2 KO
and STAT5a KO T cells exhibit impaired Th2 differentiation (3, 18). Furthermore,
retroviral-mediated expression of a constitutively active STAT5 mutant is sufficient to
drive Th2 differentiation independently of IL-4, IL-4Ra, and STAT6 but dependent on
GATA3 by promoting Il4 gene accessibility at non-overlapping regions within the locus
3

(HSII and HSIII regions by STAT5 and VA and CNS1 regions by GATA3) (19). In addition
to influencing the Il4 locus, IL-2 enhances responsiveness to IL-4 by upregulating
expression of IL-4Ra through STAT5-dependent binding to the GAS3 region in the Il4ra
locus to promote Th2 differentiation (20).
Tissue-derived cytokines (IL-33, TSLP, and IL-25)
Tissue-derived cytokines (IL-33, TSLP, and IL-25) are produced by specialized, nonhematopoietic cells in mucosal barriers upon exposure to allergens, tissue damage, or
helminth parasites. The production of these cytokines is critical for promoting type 2
effector responses from both the innate and adaptive arms of the immune system for
helminth clearance or allergen-induced immunopathology. However, the production of
these tissue-derived cytokines also directly regulates Th2 differentiation. Van Dyken et
al. demonstrated that differentiation of naïve CD4+ T cells into the Th2 lineage occurs in
a two-step process in which the initiation of Th2 differentiation and the induction of IL-4
competence occurs during T cell priming in the draining lymph nodes while terminal Th2
differentiation and the acquisition of the ability to produce IL-5 and IL-13 occurs following
T cell entry into the inflamed tissue (21). In accordance, blocking lymph node egress
using the sphingosine-1-phosphate receptor antagonist, FTY20, failed to increase the
appearance of IL-5+ and IL-13+ Th2 cells in the draining lymph nodes following infection
with Nippostrongylus brasiliensis despite no alterations in the frequency of IL-4competent Th cells, thus demonstrating that the signals for instructing full Th2
differentiation but not IL-4-competence is absent in the lymph nodes (21). Rather, the
induction of the terminal effector programs in Th2 cells was instructed by the tissuederived signals elicited by IL-33, IL-25, and TSLP because T cells doubly-deficient in
ST2 and TSLPR displayed impaired ability to produce IL-5 and IL-13 following
4

Nippostrongylus brasiliensis infection, which was further enhanced in the absence of IL25 (21).
In addition to promoting terminal Th2 differentiation, TSLP can instruct the
initiation of Th2 differentiation in a STAT5-dependent manner that can occur though IL4-dependent and IL-4-independent routes (22, 23). Moreover, TSLP can repress the
induction of Bcl-6 in a STAT5-dependent manner to selectively promote Th2
differentiation rather than differentiation into the follicular helper T (Tfh) cell lineage (23).
Furthermore, TSLP can induce a pathogenic Th2 program, which is accompanied by low
expression of IL-4 and Bcl-6 and high expression of IL-5, IL-9, IL-13, and GATA3, to
drive the generation of IL-4neg Th2 effector cells in vivo (23, 24).
Role of costimulatory-driven signals in Th2 differentiation
CD28
CD28 is a costimulatory molecule expressed on T cells and binds the B7-1 (CD80) and
B7-2 (CD86) molecules expressed on many different cell types, including professional
antigen-presenting cells (APC). Engagement of CD28 is critical for full activation of T
cells following TCR activation and preventing anergy induction. In addition to regulating
T cell activation, CD28 costimulatory signals can also influence Th2 differentiation.
Seder et al. demonstrated that ligation of CD28 is required for the induction of Th2
differentiation following activation of CD4+ TCR transgenic T cells in the presence of
APCs lacking B7 molecules (25). Furthermore, blockade of B7-CD28 interactions using
CTLA4-Ig impaired Th2 differentiation by T-cell depleted APCs (25). Mechanistically,
impairment of Th2 differentiation in the absence of CD28-mediated costimulatory signals
could be overcome by the addition of exogenous IL-2, suggesting that CD28 promotes
5

Th2 differentiation by augmenting IL-2 production (25). In contrast, other groups have
suggested that the effects of CD28 costimulation on promoting Th2 differentiation occurs
through an IL-2-independent but IL-4-dependent mechanism (26, 27). Accordingly, Kubo
et al. demonstrated that engagement of CD28 enhances the sensitivity and
responsiveness of the IL-4 receptor to promote IL-4-mediated Th2 differentiation (28).
Overall, these data suggest that CD28 is critical for the induction of Th2 differentiation
potentially through multiple mechanisms.
OX40
OX40 is a costimulatory molecule from the tumor necrosis factor receptor (TNFR)
superfamily. While not expressed in naïve T cells, OX40 expression is transiently
induced 12 hours following TCR activation (29). Expression of OX40 remains elevated
until 4-5 days after TCR activation, and can be rapidly induced upon TCR restimulation
(29). While engagement of OX40 does not significantly influence initial CD4+ T cell
activation and proliferation, OX40 activation helps sustain T cell proliferation, cytokine
production, and survival at the effector stage (29, 30).
OX40 costimulation can also instruct Th2 differentiation by regulating early IL-4
production in CD4+ T cells following TCR activation (31-33). So et al. demonstrated that
the absence of OX40-OX40L interactions, either due to genetic deletion of OX40 or the
addition of a blocking antibody against OX40L, could attenuate Th2 differentiation
following activation of CD4+ TCR transgenic T cells in the presence of APC and cognate
peptide in vitro (33). Mechanistically, OX40 costimulation promoted early IL-4
transcription by enhancing nuclear translocation of NFATc1 in an IL-4R-independent but
calcineurin and PI3K-dependent manner (33). Consistent with this notion, Th2
6

generation has been shown to be diminished in OX40 KO mice subjected to an OVAinduced model of asthma and following infections with Leishmania major and
Heligmosomoides polygyrus in vivo (34-36).
ICOS
ICOS is a member of the CD28 superfamily of receptors and binds to ICOSL that is
expressed primarily on professional APCs, such as B cells, dendritic cells (DC), and
macrophages, as well as on endothelial and alveolar type II cells (37). Similar to OX40,
ICOS is not expressed in naïve T cells but is upregulated after TCR activation (38, 39).
Triggering of ICOS promotes T cell proliferation and enhances the secretion of various
cytokines, such as IL-4, IL-10, IFNg, but not secretion of IL-2 following TCR activation
(38, 39).
ICOS expression is high in Th2 cells and costimulatory signals delivered by ICOS
can promote Th2 responses because blocking ICOS interactions in mice impairs Th2
generation following OVA-induced asthma induction or infection with Nippostrongylus
brasiliensis (40, 41). However, the mechanism by which ICOS regulates the
differentiation of naïve CD4+ T cells into the Th2 lineage is not entirely clear. Nurieva et
al. reported that ICOS activation promotes Th2 generation by directly enhancing IL-4Rindependent early IL-4 transcription in T cells following TCR activation to instruct Th2
differentiation (42). Specifically, ICOS promoted the upregulation and nuclear
translocation of NFATc1 and was potentially important for the induction of c-Maf to
potentiate early IL-4 transcription (42). In contrast, Watanabe et al. demonstrated that
the ligation of ICOS did not impact early IL-4 transcription or NFATc1 nuclear localization
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in T cells (43). Instead, activation of ICOS promoted Th2 differentiation by enhancing IL4R signaling through an unknown mechanism (43).
Notch
Notch receptors are an evolutionarily conserved family of receptors that are important for
regulation of a variety of cell processes, including cell proliferation, differentiation,
survival, and death (44). Notch receptors can bind to two classes of membrane-bound
Notch ligands, which are the Jagged ligand family (Jagged1 and Jagged 2) or the Deltalike ligand family (DLL1, DDL3, and DDL4) (44). For T cells, the Notch signaling pathway
is critical for T cell development by inducing commitment of multipotent hematopoietic
progenitor cells to the T lineage decision and maintenance of the T lineage program as
early thymic progenitors (ETP) progress through ab T cell development in the thymus
(45-47).
In addition to T cell development, engagement of the Notch signaling pathway is
important for Th2 differentiation. Early reports demonstrated the activation of the Notch
signaling pathway was critical for Th2 differentiation because loss of Notch signaling by
either deletion of RBPJk, the major transcriptional effector for Notch signaling, or
expression of a dominant negative MAML protein, a scaffold protein important for Notch
transcriptional activation complex, attenuated Th2 differentiation in vitro and impaired the
generation of protective Th2 responses against Trichuris muris in vivo (48, 49).
Mechanistically, Gata3 and Il4 were direct transcriptional targets of Notch and
engagement of Notch signaling regulated transcription of both genes in IL-4/STAT6independent manner to promote optimal Th2 differentiation (48, 50). However, it is now
appreciated that Notch acts as a broad regulator of Th differentiation by promoting
8

multiple Th lineage programs through direct transcriptional activation of Th2-specific (Il4
and Gata3) and non-Th2 targets (Tbx21, Ifng, Il17a, Rorc) rather than instructing specific
helper T cell lineage choice (51-54).
Role of TCR-mediated signal strength in Th2 differentiation
While cytokine and costimulatory signals are important for instructing Th2
differentiation, the strength and duration of TCR signaling can also contribute to the
outcome of Th differentiation. Early reports demonstrated that activation of CD4+ TCR
transgenic T cells in the presence of APCs and high doses of cognate peptide, which are
conditions that elicit strong and prolonged TCR signaling, resulted in preferential
differentiation toward the Th1 lineage (55, 56). In contrast, T cell activation by APCs
given low doses of cognate peptide, which are conditions that elicit weak and transient
TCR signaling, potentiated Th2 differentiation (55, 56). Accordingly, activation of CD4+
TCR transgenic T cells with altered peptide ligands (APL), which are cognate peptides
with signal amino acid substitutions that result in lower affinity TCR interactions,
promoted Th2 differentiation as compared to activation with WT peptides (57, 58).
Similarly, lowering TCR affinity for cognate peptide-MHC complexes by the introduction
of a point mutation (L51 à S51) in the CDR2 region of the TCRa chain of the D10 CD4+
TCR transgenes to generate L51S CD4+ TCR transgenic T cells altered Th
differentiation toward Th2 and away from Th1 following TCR activation with high doses
of cognate peptide (59). Overall, these results demonstrate that weak TCR signaling
promotes differentiation of naïve CD4+ T cells into the Th2 lineage.
The strength of TCR signaling instructs Th differentiation by regulating early Tcell-intrinsic IL-4 transcription through a TCR-dependent but IL-4R-independent
9

mechanism. Weak TCR signaling induces the early upregulation of GATA3 in an IL-2independent and IL-4-independent manner (60). TCR-mediated early GATA3 induction
works in conjunction with IL-2-mediated STAT5 signaling to promote accessibility of Il4
locus to drive early IL-4 transcription in the first 14-24 hours following TCR activation
independently of IL-4 signaling (3, 60). Subsequently, secretion of IL-4 protein then
further reinforces GATA3 induction during the polarization phase of Th differentiation
through an IL-4R/STAT6-dependent mechanism to potentiate Th2 differentiation (61).
Augmenting TCR signaling can block this process of early IL-4 transcription
through multiple mechanisms. Similar to previous reports, Yamane et al. demonstrated
that activation of CD4+ TCR transgenic T cells with APCs and high doses of cognate
peptide, which mimics strong TCR signaling, blocked Th2 differentiation by dampening
early GATA3 induction and IL-4 transcription (60). Importantly, they found that TCRmediated ERK signaling was a key determinant in regulating Th differentiation because
inhibition of ERK signaling using the MEK inhibitor, U0126, could restore Th2
differentiation at these high peptide concentration conditions through upregulation of
early GATA3 expression and IL-4 transcription (60). Additionally, strong TCR-mediated
ERK signaling blocked IL-2R-mediated STAT5 activation independently of the effects of
ERK signaling on GATA3 to attenuate Th2 differentiation (60). However, despite the
importance of strong TCR-mediated ERK signaling in blocking early GATA3 induction
and promoting IL-2R desensitization to suppress Th2 differentiation, the molecular
mechanisms through which ERK mediates these effects are not entirely understood.
Interestingly, Jorritsma et al. suggested that weak TCR-mediated ERK signaling either
by activation with APLs or through inhibition of ERK signaling can promote Th2
differentiation through an alternative mechanism by altering the composition of TCR10

mediated activation of AP-1 complexes from Fos-JunB heterodimers to more JunB-JunB
homodimers (58). However, evidence that alterations in AP-1 complex formation by
changes in TCR-signal strength directly instructs Th differentiation is lacking. Overall, the
data supports that TCR signal strength regulates Th2 differentiation through the
regulation of early T cell-intrinsic IL-4 production.
Given that the lipid molecule diacylglycerol (DAG) is the main driver of TCRmediated ERK activation, the following sections will review the regulation of DAG by
diacylglycerol kinases (DGK) and the various roles that DGKs play in regulating immune
cell function.
Regulation of DAG by diacylglycerol kinases (DGK)
Diacylglycerol (DAG) is a key secondary lipid messenger for transducing signals
downstream of many receptors expressed by hematopoietic cells. DAG has shown to be
important in driving the activation, proliferation, migration and effector function of adaptive
and innate immune cells. The generation of DAG can be accomplished by the activation
of various cell-surface receptors, including Gq-mediated G-protein coupled receptors
(GPCR)s (e.g., muscarinic and histamine receptors) and immunoreceptor tyrosine-based
activation motif (ITAM)-bearing receptors (e.g., T cell receptor (TCR), FcεRI) (62-65). The
activation of these receptors results in the formation of proximal signaling complexes that
are critical for the activation of phospholipase C (PLC). PLC activation leads to enzymatic
cleavage of phosphoinositol 4,5-bisphosphate (PIP2) into DAG and inositol 1,4,5triphosphate (IP3) (66). While IP3 mobilizes Ca2+, DAG activates the NF-kB and
extracellular regulated kinase (ERK) pathways through protein kinase C (PKC) and
RasGRP, respectively, to promote cell function (67-72). Consequently, the levels of DAG
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must be tightly regulated to control the magnitude and duration of the responses
generated.
Diacylglycerol kinases (DGK) are negative regulators of DAG-mediated signaling.
DGKs regulate DAG signaling by phosphorylating DAG and converting it into phosphatidic
acid (PA) (64, 73). The loss of DGKs increases DAG levels and the duration of DAGmediated signaling. One might expect that elevated DAG levels would lead to general
enhancement of effector responses. However, the enhancement of DAG signaling through
the loss of DGKs can lead to either hyperactivation or hyporesponsiveness depending on
the cell type and the type of response. There are 10 different isoforms comprising 5
different classes of DGKs, each of which control different cellular functions based on their
distinct structural motifs and subcellular localization (64, 73-76). The three major isoforms
that are abundantly expressed in lymphoid tissues are DGKa, DGKd, and DGKζ (77). In
particular, mice that lack the zeta (ζ) isoform of DGK, which is highly expressed in
hematopoietic cells, display profound effects on the functional behavior of various cell
types. In following sections, we will focus on how DGKζ plays both negative and positive
roles in immune responses mounted by different cell types.
Negative regulation of effector responses by DGKζ
CD4+ and CD8+ conventional T cells
DGKζ serves as a critical negative regulator of DAG signaling downstream of the TCR
and can modulate the strength of TCR signaling. Early experiments using the immortalized
Jurkat T cell line showed that overexpression of DGKζ inhibits TCR signaling by reducing
the levels of active GTP-bound Ras and, consequently, diminishing ERK activation (78).
Furthermore, the overexpression of DGKζ was associated with decreased AP-1
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transcription factor activity and CD69 expression (an early T cell activation marker)
following TCR stimulation, both of which are regulated by the Ras-ERK pathway.
Importantly, Ca2+ flux was normal regardless of DGKζ overexpression, suggesting that
DGKζ selectively regulated DAG-mediated signaling pathways downstream of the TCR.
Further biochemical analysis through the use of a kinase dead DGKζ mutant revealed that
the enzymatic activity of DGKζ was critical for its inhibitory effects on TCR signaling.
To test the physiological role of DGKζ in T cells, Zhong et al. generated DGKζ
knockout mice (79). Initial phenotypic analysis showed that DGKζ KO mice contained
similar frequencies and numbers of CD4+ and CD8+ T cells in secondary lymphoid organs
and displayed no obvious defects in lymphoid architecture or cellularity. Furthermore,
thymic development as analyzed by the number and frequency of CD4 single-positive
(SP), CD8 SP, double-positive (DP), and double-negative (DN) thymocytes in DGKζdeficient mice was similar to wild-type (WT) mice. However, upon TCR stimulation, naïve
DGKζ KO CD4+ and CD8+ T cells displayed enhanced upregulation of activation markers
CD25 and CD69 and increased proliferation compared to WT T cells. The increased
expression of activation markers was associated with enhanced phosphorylation of ERK
but normal induction of non-DAG mediated pathways including Ca2+ flux and JNK
activation. Importantly, bypassing TCR activation with a DAG analogue, phorbol-12myristate-13-acetate (PMA), abolished differences in activation between DGKζ KO and
WT T cells, suggesting that the hyperactivation of DGKζ KO T cells was secondary to
defective regulation of DAG.
In agreement with enhanced TCR signaling, DGKζ KO T cells also display
improved anti-viral responses (79). DGKζ KO mice infected with LCMV Armstrong showed
enhanced viral-specific T cell responses as evidenced by decreased viral titers at day 7
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following infection. This effect correlated with an increased number of total and
CD44hiCD62Llo effector CD8+ T cells in the spleen. Furthermore, LCMV-infected DGKζ KO
mice exhibited increased number of IFNg-producing CD8+ and CD4+ T cells when
restimulated with LCMV-specific peptides, suggesting that DGKζ KO T cells displayed
enhanced effector function following LCMV infection.
Similarly, DGKζ-deficient mice also exhibit enhanced anti-tumor responses. DGKζ
KO mice subcutaneously injected with OVA-expressing EL4 T cell lymphoma, had
significantly reduced tumor mass compared to their WT counterparts (80). This effect was
accompanied by an increased number of total and antigen-specific tumor-infiltrating
CD44hiCD8+ T cells. To show that T cells were responsible for the enhanced anti-tumor
effect by DGKζ deficiency, DGKζ KO and WT OVA-specific OT-I T cells were adoptively
transferred into naïve recipient WT mice. Mice receiving DGKζ KO compared to WT OVAspecific OT-I T cells also exhibited lower tumor mass upon challenge with OVA-expressing
EL4 cells. Isolation of tumor-infiltrating OT-I cells revealed that the loss of DGKζ increased
the frequency of CD44hi and IL-2-producing OT-I cells in a cell-intrinsic manner. In addition
to preventing tumor engraftment, DGKζ deficiency also improves tumor rejection of
established tumors, as the adoptive transfer of DGKζ KO but not WT OT-I effector T cells
into tumor-bearing mice significantly reduced tumor burden (81). Thus, DGKζ could
represent a novel target for enhancing anti-tumor responses in adoptive immunotherapy.
This could also be applied to engineered T cells that express chimeric antigen receptors
(CAR) directed against the tumor, as DGKζ deficiency was also shown to promote CAR T
cell-mediated anti-tumor responses (81). How DGKζ deficiency augments anti-tumor
responses is unclear. Although DGKζ KO CD8+ T cells display increased cytokine
production and increased proliferation, their cytotoxic function is comparable to WT CD8+
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T cells (80). Nevertheless, these studies demonstrate that DGKζ serves to constrain T cell
activation and anti-viral and anti-tumor T cell responses. Thus, inhibition of DGKζ might
provide a therapeutic opportunity to enhance immune-mediated viral and tumor clearance.
It is possible that DGKζ is physiologically important for limiting over-activation and
inducing anergy in inappropriately activated T cells. The expression level of DGKζ can be
controlled depending on the type of stimulation the T cell receives. T cells that are
stimulated through their TCR and co-stimulatory molecules downregulate DGKζ transcript
levels, thereby allowing appropriately activated T cells to become fully activated (82-84).
In contrast, T cells that receive TCR stimulation alone in the absence of co-stimulation do
not downregulate DGKζ levels, potentially leading to attenuated DAG-mediated signaling
and decreased activation. Consistent with this notion, DGKζ KO T cells resist anergy
induction when activated by TCR alone in the absence of co-stimulatory signals (83). In
addition to TCR-mediated regulation, DGKζ might also be regulated by environmental
cytokines. In particular, IL-33 has been shown to up-regulate DGKζ in cardiomyocytes
following stimulation (85). Although it is unknown if IL-33 can upregulate DGKζ in immune
cells, it is tantalizing to speculate that cytokine signaling can affect the TCR
responsiveness of T cells by regulating DGKζ levels.
NK cells
NK cells are cytotoxic members of the innate lymphoid cell (ILC) family and play an
important role in protection against viral infection and clearance of tumors (86). Unlike
their adaptive counterparts (CD8+ T cells), they do not possess a somatically-rearranged
antigen receptor but rather express a variety of activating receptors specific for ligands
displayed on virally-infected, stressed, or transformed cells (87). NK cell activating
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receptors can be categorized into three main families based on the signaling adaptors
used to relay downstream activation signals. These families include SAP-dependent (e.g.,
2B4), ITAM-dependent (e.g., CD16), or DAP10-dependent (e.g., NKG2D) receptors (8790). The activation of any of these three families of receptors relies on proximal signaling
complexes involving SLP-76, which subsequently leads to the activation of PLCg and the
production of DAG (91-93). In addition to these activating receptors, NK cells express an
assortment of inhibitory receptors, many of which bind to MHC class I alleles and
negatively regulate activating receptor signaling by the recruitment of phosphatases such
as SHP-1 and SHIP (87, 94).
NK cell activation is determined by the net balance of the activating and inhibitory
inputs that the NK cell receives through its receptors. For example, NK cells are activated
when neoplastic cells upregulate ligands such as RAE-1 or MICA, which are recognized
by the activating receptor NKG2D (95). Likewise, NK cells are activated through
disinhibition when tumor cells lose MHC class I, a process known as missing selfrecognition (96). Since SHP-1 and SHIP negatively regulate activating receptor signaling,
one might predict that the loss of these molecules would boost the effector function of NK
cells. Surprisingly, however, SHP-1 and SHIP deficiency in NK cells renders them less
functional than their WT counterparts (97-99). One explanation of this seemingly
paradoxical finding is that NK cells continuously adjust their responsiveness to activating
stimuli in their local environment, a phenomenon known as tuning (100). Thus, NK cells
that chronically lack inhibitory signals, such as in SHP-1 or SHIP deficiency, require more
stimulation to achieve their threshold of activation (97-99). While NK cell tuning may
protect the host from NK cell-mediated immunopathology, this process can hamper
important effector responses against chronic viral infections or tumors.
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Although the molecular mechanism of NK cell tuning is unknown, stimulation of NK
cells with PMA and a calcium ionophore, ionomycin, can bypass the hyporesponsiveness
of SHP-1 and SHIP KO NK cells (97, 99). These data suggest that the tuning process is
proximal to PLCg-mediated production of DAG. Thus, we speculated that NK cells may
not be able to tune their responsiveness in response to enhanced DAG-mediated signaling
by DGKζ deficiency. Indeed, we recently demonstrated that DGKζ KO NK cells are
hyperfunctional compared to WT NK cells (101). DGKζ KO NK cells displayed increased
cytokine production and cytotoxicity following stimulation through ITAM, SAP, and DAP10dependent activating receptors. In contrast, IFNg production by DGKζ KO and WT NK
cells was similar following stimulation with IL-12 and IL-18, which utilize a DAGindependent signaling pathway, suggesting that the loss of DGKζ selectively augmented
NK cell responsiveness to DAG-dependent stimuli. Like T cells, the hyperfunctionality of
DGKζ KO NK cells was dependent on enhanced ERK signaling. Importantly, DGKζ KO
mice cleared the NK cell-sensitive RMA-S tumor more efficiently than WT mice. Thus, the
inactivation of negative regulators distal to PLCg such as DGKζ might prove therapeutically
useful in enhancing NK cell function.
B cells
B cells comprise the second arm of the adaptive immune system and are critical for the
generation of protective antibody responses during infection. The induction of antibody
production results from the stimulation of the somatically rearranged B cell receptor (BCR)
by cognate antigen (102, 103). Similar to the TCR, activation of the BCR leads to
downstream biochemical cascades that ultimately result in the generation of DAG through
PLCg and, subsequently, the activation of ERK (104, 105). ERK has been shown to play
multiple roles during B cell responses, including the promotion of B cell survival,
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proliferation, and differentiation into antibody-secreting plasma cells (106-108).
Furthermore, attenuation of ERK activation has been shown to important during B cell
development, since ERK signals decrease as B cells progress from the immature
transitional stage to mature follicular B cells (109-111).
Given the role of ERK in these B cell processes, controlling the levels of BCRinduced DAG through DGKζ might be important in regulating B cell development,
activation, and antibody secretion capabilities. For example, mRNA transcripts of DGKζ
are upregulated as B cells progress from early transitional to the mature follicular stage,
which is associated with decreased ERK activation (112). Accordingly, the loss of DGKζ
only affected ERK activation and IkBa degradation in the follicular but not early immature
transitional B cell pool in response to BCR stimulation. Importantly, the augmentation of
BCR-induced activation in DGKζ KO follicular B cells was seen even under less optimal
BCR activation conditions, suggesting that DGKζ might control the BCR activation
threshold in these cells.
The effects of DGKζ on B cell signaling threshold translate to functional
consequences on B cell effector responses. BCR stimulation of purified DGKζ KO splenic
B cells in vitro led to increased expression of CD69 and enhanced proliferation compared
to WT B cells. DGKζ KO mice displayed enhanced antibody responses to T-independent
and T-dependent antigens (112). The heightened antibody response by DGKζ-deficiency
was accompanied by increased antigen-specific expansion of both germinal center (GC)
B cells and plasma cells. These results demonstrate that regulation of DAG-dependent
ERK activation by DGKζ is critical for selectively controlling the activation threshold of
mature B cells to limit their activation.
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The immunomodulatory role of DGKζ
We have so far described how the loss or inhibition of DGKζ can lead to increased immune
responses against viruses or cancer. As DGKζ is a negative regulator of DAG-mediated
signaling, it is conceivable that immune responses would be enhanced in the absence of
DGKζ. However, DGKζ deficiency may also lead to dampening or regulation of immune
responses. In the sections below, we will discuss how the absence of DGKζ can direct
and indirectly suppress or modulate rather than enhance immune responses.
Regulatory T Cells
Regulatory T cells (Tregs) are a key subset of T cells that display suppressive function
and are important for the regulation of adaptive immune responses. Tregs are governed
by the master transcription factor, forkhead box P3 (Foxp3), and exert their
immunosuppressive function via the production of immunoregulatory cytokines and
through cell contact dependent mechanisms (113). Loss of function mutations in the
Foxp3 gene, as seen in Scurfy mice and humans with immune dysregulation,
polyendocrinopathy, and X-linked lymphoproliferative disease (IPEX), leads to lethal
systemic autoimmunity early in life, highlighting the importance of Tregs in inducing
immunotolerance against self-antigens (114-117)
T cells that strongly recognize self-antigens are deleted during thymic development
in a process known as negative selection. Specifically, T cells that receive strong TCR
signals in the thymus, implying overt self-reactivity, undergo apoptosis. As an alternative
fate, strong TCR stimulation in developing thymocytes can also lead to Treg differentiation
(113). Thus, we hypothesized that enhancement of TCR-mediated DAG signaling by
DGKζ deficiency in developing thymocytes may increase Treg generation. Indeed, the
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loss of DGKζ resulted in a significant increase in Treg development in the thymus in a cellintrinsic manner (118). DAG-mediated signaling leads to the activation of the NF-kB
(through activation of PKC) and ERK pathways. One NF-kB family member, c-Rel, was
previously shown to be important for inducing Foxp3 expression in thymocytes (119, 120).
Although Treg generation in DGKζ KO mice was reduced in the absence of c-Rel, there
was still residual Tregs in the thymus, suggesting that c-Rel was only partially responsible
for the increased generation of Tregs in DGKζ KO mice (118). In fact, ERK activation
appeared to be more important in the enhancement of Treg generation in DGKζ KO mice.
Using an in vitro Treg development assay, we found that the inhibition of ERK
phosphorylation by a MEK inhibitor led to decreased Treg generation in a dose-dependent
manner, whereby the level of phosphorylated ERK (pERK) directly correlated to the
magnitude of Treg generation. Importantly, Treg generation was also increased in
sevenmaker mice (121), which express a gain of function ERK mutation that leads to
increased resistance to dephosphorylation of active pERK, suggesting that the selective
enhancement of the ERK pathway alone is sufficient to increase Treg generation.
In addition to Treg generation in the thymus, TCR signaling plays an important role
in the function of Tregs. Although some Treg function may be preserved in the absence
of TCR signaling, we demonstrated that Tregs lacking SLP-76 cannot suppress TCRdriven proliferation of conventional T cells (122). Furthermore, Tregs with a YàF mutation
at tyrosine 145 (Y145F) of SLP-76, which leads to defective PLCg activation, also display
attenuated suppressive function, suggesting that PLCg is important for Treg function.
Consistent with this notion, Tregs lacking DGKζ display significantly increased
suppression of TCR-driven conventional T cell proliferation compared to WT Tregs.
Together, these data demonstrate that DGKζ limit Treg generation and function. Thus,
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DGKζ deficiency may indirectly lead to the suppression of immune responses through
Tregs.
Mast Cells
Mast cells are critical mediators in type 2 immune responses involved in protection against
helminthes and in pathologic responses in asthma and allergy (123, 124). A key feature
of mast cell function is the immediate release of pre-formed inflammatory mediators such
as histamine, cytokines, and proteases in a process called degranulation. In addition, mast
cells produce arachidonic acid metabolites and cytokines in a protracted manner (124).
One major stimulus for the release of these inflammatory mediators is crosslinking of
FceRI, the high affinity receptor for the Fc region of immunoglobulin E (125).
The interaction of allergens with IgE-FceRI complexes results in formation of
signaling complexes that converge on the activation of PLCg (126, 127). PLCg and
subsequent PKC activation have been shown to be critical in controlling mast cell
degranulation, suggesting that controlling the levels of DAG might be important for
regulating this process (128-131). Indeed, the loss of DGKζ in FceRI-stimulated mast cells
leads to increased DAG levels, along with enhancement of downstream DAG-dependent
signals, including RasGTP and ERK (132). Accordingly, DGKζ deficiency leads to
enhanced mast cell production of IL-6 following FceRI stimulation.
Intriguingly, however, FceRI-stimulated DGKζ KO mast cells display impaired
degranulation and are resistant to local skin anaphylaxis (132). The differential effect of
DGKζ deficiency on mast function (the hypersecretion of IL-6 vs. decreased
degranulation) may be explained by the negative feedback of DAG on PLCg activation in
mast cells. The elevation of DAG by DGKζ deficiency appears to negatively regulate the
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phosphorylation and subsequent activity of PLCg. Thus, although DAG accumulates, the
production of IP3, and hence Ca2+ flux is attenuated in DGKζ KO mast cells.

As

degranulation responses are highly dependent on elevation of intracellular Ca2+ levels,
this may cause a differential effect on degranulation and cytokine production by mast cells
(132, 133). Thus, as opposed to T cells and NK cells, DGKζ exerts both activating and
inhibitory effects on mast cell functional responses.
Macrophages and Dendritic Cells
Macrophages and dendritic cells (DC) play a key role in bridging the adaptive and innate
immune responses (134-136). Toll-like receptors (TLR) serve as an important mechanism
for equipping macrophages and DCs with the ability to recognize the presence of
pathogenic infection and, subsequently, instruct adaptive immune cells on the type of
response needed to effectively clear the infection. TLRs can signal through either MyD88
and/or TRIF to induce activation of the NF-kB and ERK pathways (134). While TLR
activation does not generally lead to PLCg activation, DAG has been shown to be induced
in macrophages following stimulation with LPS (TLR4 agonist) and lipopeptide (TLR2
agonist) (137-139). Furthermore, inhibition of PLC or PLD reduced cytokine production
and nitric oxide formation by macrophages following TLR stimulation, suggesting that
control of DAG levels through DGK might be important in regulating TLR-mediated
responses.
Interestingly, modulation of DAG levels by the loss of DGKζ resulted in impairment
rather than enhancement of cytokine production by macrophages and DCs in response to
TLR stimulation. Specifically, in a developmentally independent manner, bone marrow
derived macrophages (BMMF) and splenic DCs produced substantially less IL-12p40 and
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TNFa following in vitro stimulation through a variety of TLR agonists (140). This
paradoxical finding may be explained by the role of DGK in converting DAG into PA.
Biochemical analysis revealed that the loss of DGKζ resulted in selective elevation of the
PI3K-Akt pathway but no difference in activation of the ERK or NK-kB pathways following
TLR stimulation. Activation of the PI3K pathway has been shown to negatively regulate
TLR stimulation (141-143) and chemical inhibition of the PI3K restored LPS-induced IL12p40 production from DGKζ KO BMMFs (140). Intriguingly, the addition of PA also
restored LPS-induced IL-12p40 production, suggesting that the cytokine production defect
in DGKζ KO DCs and macrophages may be due to reduced PA rather than elevated DAG
levels. Exactly how PA rescues TLR-induced cytokine production is unknown, but one
possible mechanism is through the recruitment of SHP-1 to negatively regulate PI3K
activation (144-146).
Defective cytokine production was also observed in vivo following intraperitoneal
injection of TLR agonists, which correlated with enhanced survival of DGKζ KO mice after
LPS-induced septic shock (140). However, while DGKζ KO mice were protected from
TLR-mediated pathology, the loss of DGKζ conferred susceptibility to Toxoplasma gondii.
DGKζ KO mice infected with Toxoplasma gondii displayed decreased serum IL-12p40 and
IFNg levels compared to WT mice. Furthermore, IFNg production by DGKζ KO splenocytes
isolated at day 15 and 30 post-infection was significantly attenuated following restimulation
with T. gondii antigen STAg. Intriguingly, total CD4+ and CD8+ T cell numbers were similar
between WT and DGKζ KO mice following infection with the frequency of CD44+CD62lo
effector T cells higher in infected DGKζ KO mice. As TLR-induced IL-12p40 production
and the subsequent induction of a Th1 response are critical for protection against
Toxoplasma gondii infection, the impairment of immune responses against T. gondii by
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DGKζ KO mice could be secondary to a defect in macrophage and DC-derived cytokines
that drive Th1 responses.
The role of other DGK isoforms on DGKζ-regulated immune function
So far, we have discussed isoform-specific regulation of immune function by DGKζ,
however it is possible that the loss of DGKζ has other functional consequences that might
be masked by redundant functions of other DGK isoforms. Indeed, DGKa has been shown
to display some redundant function with DGKζ during conventional T and invariant NKT
cell (iNKT) development. While singly-deficient DGKa KO and DGKζ KO mice display no
gross defects in thymic T cell development, mice deficient in both DGKa and DGKζ
(DGKaζ DKO) have significant reductions in CD4 and CD8 SP populations in the thymus
due to a cell-intrinsic block in positive selection from the DP to SP stage (147).
Interestingly, the addition of PA to fetal thymic organ cultures could partially restore T cell
maturation defect in DGKaζ DKO thymocytes, suggesting that DGKa and DGKζ regulate
T cell development partly through redundant production of PA.
Similarly, the development of iNKT cells is intact in mice singly-deficient for either
DGKa or DGKζ (148). However, the loss of both DGKa and DGKζ results in a complete
impairment of iNKT cell maturation in the thymus, spleen, and liver at both early and
terminal stages in a cell-intrinsic manner. Selective enhancement of the ERK pathway
through the expression of a constitutively active K-ras resulted in a significant reduction in
mature iNKT cells due a block in Stage II to Stage III maturation of iNKT precursors.
Furthermore, augmented activation of the NF-kB pathway through the expression of a
constitutively active IKKb also resulted in an impairment in iNKT maturation at both early
and terminal stages of development. These results suggest that DGKa and DGKζ play
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redundant roles in the regulation of iNKT maturation by controlling DAG-mediated
activation of the ERK and NF-kB pathways.
In addition to controlling innate and conventional T cell development, DGKa has
also been shown to promote T cell anergy in conjunction with DGKζ. Overexpression of
either DGKa or DGKζ in Jurkat T cells induces an anergic-like state that is highlighted by
reduced DAG-dependent TCR signals without the impairment of calcium flux (83). Similar
to DGKζ KO T cells, T cells deficient in DGKa resist anergy induction when activated
through their TCR in the absence of costimulation and during superantigen-induced
activation. Furthermore, pharmacological inhibition of DGKa in DGKζ-deficient T cells can
further enhance proliferation and IL-2 production in response to anergy-inducing
conditions, suggesting that both DGKa and DGKζ contribute to anergy induction in
inappropriately activated T cells through the synergistic regulation of TCR-induced DAGmediated signaling.
While DGKa and DGKζ can share similar functions, DGKa does not simply
compensate for all DGKζ-regulated functions. For example, unlike DGKζ KO mice, DGKadeficient mice do not display an enhancement in Treg generation in the thymus or
hyperfunctional NK cell responses, thus emphasizing that the regulation of these
processes by DGKs is isoform-specific and unique to DGKζ (101, 149). The independent
and redundant roles of DGKa and other DGK isoforms on DGKζ-regulated functions in
other immune cells remain unexplored.
Structure of the thesis
While factors that regulate Th2 differentiation has been extensively studied since
the discovery of Th subsets by Tim Mosmann and Robert Coffman in the late 1980’s,
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major gaps still remain regarding the key determinants for dictating the Th2 fate decision
of naïve CD4+ T cells following T cell activation. While TCR-driven signaling is thought to
be highly important in this process, it is still not well understood how alteration of specific
TCR signal transduction pathways influence the development of this lineage. The aim of
this thesis is to investigate the role of DGKζ in modulating selective TCR-signal
transduction pathways to regulate Th2 differentiation and control type 2 immune
responses in vivo (Fig. 1.1). In addition, this thesis will also examine the novel
immunomodulatory roles of DGKζ in regulating non-immune responses that are critical
for initiating and promoting the pathological aspects of aberrant type 2 immune
responses. Chapter 2 will examine the cellular and molecular mechanisms by which
DGKζ modulates Th2 differentiation and controls T-cell mediated airway inflammation in
a mouse model of allergic asthma. Additionally, this chapter will interrogate the
relationship between inflammation and airway hyperresponsiveness and how DGKζ
influences both processes through independent mechanisms. Chapter 3 will explore
how DGKζ influences innate immune type 2 responses in the airways in response to
protease allergens and discuss a novel role for DGKζ in regulating protease allergen
sensing by the non-immune compartment to control airway inflammation. Lastly,
Chapter 4 will discuss the implications of these findings in context of what is known
about the initiation, propagation, and maintenance of type 2 immune responses.
Furthermore, this chapter will discuss the future directions for this work and the broader
implications of these pathways in sites outside of the lung.
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Figures

Figure 1.1. Enhanced TCR-mediated ERK activation in the absence of
diacylglycerol kinase zeta (DGKζ). In the absence of DGKζ, T cells display
accumulation of diacylglycerol (DAG) and, consequently, enhancement of the NF-kB
and ERK pathways following TCR ligation. Additionally, T cell lacking DGKζ also display
reduction in phosphatidic acid (PA) signaling following triggering of the TCR.
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CHAPTER 2: DIACYLGLYCEROL KINASE ZETA CONTROLS ALLERGIC AIRWAY
INFLAMMATION AND AIRWAY HYPERRESPONSIVENESS THROUGH DISTINCT
MECHANISMS
Introduction
Asthma is a chronic allergic inflammatory airway disease that affects more than 300
million people worldwide, with an annual economic cost estimated to exceed $56 billion
in the United States alone (150). The pathogenesis associated with allergic asthma is
characterized by airway inflammation that is mediated by aberrant immune responses to
inhaled allergens at the mucosal surfaces of the lung and airflow obstruction driven in
part by increased airway smooth muscle responses to contractile stimuli, in a process
known as airway hyperresponsiveness (AHR) (151-153). Current therapeutic
approaches used to treat asthma involve combinatorial administration of bronchodilators
and anti-cholinergic drugs to relax constricted airways and corticosteroids to inhibit
airway inflammation (154). While these treatments benefit many patients who have
asthmatic disease, there is a significant proportion of patients in whom these treatments
never fully control asthma, particularly in those who have severe disease (152).
Furthermore, cessation of these treatments often results in reoccurrence of asthma
symptoms and loss of asthma control, suggesting that these treatments fail to reverse
the underlying intrinsic changes in airway cells that mediate asthma pathology (155,
156). Therefore, there is an urgent unmet need for therapeutics that can offer better
control and potentially mediate resolution of the disease.
Airway inflammation present in allergic asthma is typically driven by type 2
immune responses in the lung, although other asthma endotypes driven by type 2independent immune responses do exist (157, 158). Type 2 inflammation in the lung is
mediated by Th2 CD4+ T cells and group 2 innate lymphoid cells (ILC2), which produce
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the type 2 cytokines, IL-4, IL-5, and IL-13, in response to antigen-dependent and
antigen-independent activation (159-166). The production and release of these cytokines
promote a variety of downstream responses, which include the recruitment and
activation of eosinophils in the lung, IgE production by allergen-specific B cells to arm
basophils and mast cells for degranulation, goblet cell-mediated mucus production, and
excessive airway smooth muscle contraction, that ultimately result in the damage of the
lung parenchyma and the impairment of lung function in asthma (151, 153, 162-165,
167-169). Furthermore, it is generally thought that type 2 airway inflammation drives the
non-immune abnormalities, such as AHR, that are present in asthma.
Given the role of Th2 CD4+ T cells in asthma pathogenesis, blocking Th2
differentiation of allergen-specific T cells represents a viable therapeutic strategy for the
treatment of asthma. While cytokine (e.g. IL-4, TSLP, IL-25, and IL-33) and
costimulatory (e.g. CD28, ICOS, OX40) signals are known to be important for driving
Th2 differentiation, the strength and duration of TCR signaling can also contribute to the
outcome of CD4+ T cell differentiation, in which strong and prolonged TCR-mediated
signals promote Th1 differentiation while weak and transient signals skew differentiation
toward Th2 (1, 21, 23, 26, 27, 34, 41, 55, 56, 58, 60). More specifically, TCR-mediated
ERK activation is a key determinant in driving CD4+ T cell differentiation, in which strong
ERK signals block Th2 differentiation (58, 60). TCR-mediated ERK activation is largely
dependent on DAG, which is a secondary lipid messenger that is generated upon the
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC).
DAG is negatively regulated by its phosphorylation into phosphatidic acid by
diacylglycerol kinase (DGK) enzymes. Among DGK family members, the ζ isoform of
DGK plays a predominant role in suppressing DAG-dependent ERK activation (170).
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Accordingly, T cells lacking DGKζ accumulate DAG and display enhanced ERK
activation (171).
Being a negative regulator of DAG-mediated signaling, the absence of DGKζ
would be predicted to enhance the magnitude of immune responses in general. Indeed,
this is the case in anti-tumor and anti-viral immunity, whereby DGKζ KO T cells and NK
cells display enhanced activation (171-174). However, in some instances (e.g., in
allergic responses), DGKζ KO mast cells fail to degranulate and DGKζ KO mice are
resistant to anaphylaxis (175). Thus, depending on the process, blocking DGKζ could be
either immunostimulatory or immunosuppressive (176). Given that ERK activation skews
T cell responses away from Th2 differentiation, we hypothesized that the enhancement
of DAG signaling by targeting DGKζ would suppress rather than potentiate the
development of allergic asthma. Indeed, we show that enhancement of DAG signaling
by the inhibition of diacylglycerol kinases attenuates Th2 differentiation and this effect
translated to protection from a mouse model of Th2-mediated allergic asthma.
Surprisingly, we found that the mechanisms by which DGKζ mediated airway
inflammation and AHR were separable. Conditional deletion of DGKζ in T cells led to
impairment of type 2 inflammation in an ERK-dependent manner with no attenuation of
AHR. In contrast, targeted deletion of DGKζ in smooth muscle cells led to impairment of
AHR with no attenuation of airway inflammation. Furthermore, we demonstrate that
pharmacological inhibition of DGK suppresses murine type 2 airway inflammation and
AHR and inhibits carbachol-mediated bronchoconstriction of human airways. Thus,
these data demonstrate that DGKs are novel therapeutic targets for asthma and reveal
that airway inflammation and AHR are not as interdependent as generally believed.
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Results
Conventional CD4+ T cells produce IL-4 following TCR activation to drive Th2
differentiation under nonpolarizing conditions in vitro
While IL-4 is critical for instructing Th2 differentiation, the relevant sources of IL-4
for initiating differentiation of naïve CD4+ T cells into the Th2 lineage is controversial.
Many different cell types, such as non-conventional T cells (NKT2), granulocytes
(eosinophils, basophils, and mast cells), innate lymphoid cells (ILC2), have been
implicated as a relevant source of IL-4 for driving Th2 differentiation in vivo (7-13).
However, previous work has shown that conventional CD4+ T cells can be an early
source of IL-4 immediately following TCR activation that is sufficient to promote Th2
differentiation in the absence of exogenous cytokines (14-16). We found that activation
of naïve CD4+ T cells under nonpolarizing conditions with anti-CD3 and anti-CD28 in the
presence of irradiated CD4-depleted splenocytes in the absence of exogenous cytokines
resulted in robust generation of Th2 cells that expressed high levels of GATA3 and Th2
cytokines, IL-4, IL-5, and IL-13 (Fig 2.1, A). Strong Th2 development under these
conditions was dependent on STAT6 signaling because Th2 differentiation was
completely blocked in STAT6 KO T cells (Fig. 2.1, B and C). Activation of T cells in the
presence of neutralizing antibodies to IL-4 completely diminished Th2 generation
following TCR activation, thus revealing that the induction of Th2 cells was dependent on
IL-4 signaling (Fig. 2.1, D). To determine the source of IL-4 for instructing Th2
differentiation in this system, we activated WT and IL-4 KO T cells with either WT or IL-4
KO irradiated CD4-depleted splenocytes. To our surprise, Th2 differentiation was
completely intact in T cells activated with IL-4 KO irradiated feeders (Fig. 2.1, E).
However, if T cells were deficient in IL-4, Th2 differentiation was completely lost
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following TCR activation (Fig. 2.1, E). Overall, these data demonstrated that
conventional CD4+ T cells produce relevant amounts of IL-4 immediately following TCR
activation to instruct Th2 differentiation in the absence of exogenous sources of IL-4 in
vitro.
DGKζ KO T cells display impaired Th2 differentiation in vitro
ERK activation has been shown to drive T cells to differentiate into Th1 over Th2
phenotype (58, 60). Since ERK is hyperactivated in the absence of DGKζ in T cells, we
first tested if DGKζ knockout (KO) T cells display impaired Th2 differentiation in vitro.
When naïve CD4+ T cells from DGKζ KO mice were stimulated through their TCR and
expanded in vitro under nonpolarizing conditions, the proportion of Th1 cells was
increased while the proportion of Th2 cells was decreased compared to naïve CD4+ T
cells from WT mice (Fig. 2.2, A and B). To determine if the attenuation of Th2
differentiation in the DGKζ KO T cells was due to impaired endogenous IL-4 production,
naïve DGKζ KO CD4+ T cells were activated through their TCR in the presence of
exogenous IL-4. Indeed, Th2 differentiation was completely restored in DGKζ KO T cells
treated with exogenous IL-4 (Fig. 2.2, C and D). Induction of early IL-4 transcripts is
detectable within ~1 hour following TCR activation while production of IL-4 protein is
detectable ~48 hours after TCR activation in an IL-4R-independent manner, suggesting
that autocrine/paracrine secretion and sensing of IL-4 by conventional CD4+ T cells is
required at approximately 48 hours following TCR activation to promote Th2
differentiation. To test if restoration of IL-4 levels within this initial 48-hour window was
sufficient to restore Th2 differentiation in DGKζ KO T cells, exogenous IL-4 was added at
either 0, 24, 48, 72, or 96 hours after TCR activation. Indeed, we found that addition of
exogenous IL-4 within 48 hours following TCR activation was sufficient to restore Th2
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differentiation in DGKζ KO T cells (Fig. 2.2, E-H). These data reveal that the loss of
DGKζ attenuates Th2 differentiation by likely impairing early TCR-mediated, T-cell
intrinsic IL-4 production.
DGKζ KO mice are protected from OVA-induced allergic airway inflammation and AHR
To test whether this reduction in Th2 differentiation would correlate with protection
against asthma in DGKζ KO mice, WT and DGKζ KO mice were subjected to an OVAinduced allergic asthma mouse model. In line with our in vitro data, OVA-challenged
DGKζ KO mice exhibited significantly reduced total inflammatory cell and eosinophil
numbers in the bronchoalveolar lavage (BAL) fluid, decreased BAL Th2 cytokine levels,
and diminished OVA-specific IgG1 serum antibody levels compared to OVA-challenged
WT controls (Fig. 2.3, B-D). This correlated with decreased inflammatory infiltrates in the
lungs of OVA-challenged DGKζ KO mice (Fig. 2.3, E). Importantly, AHR was almost
completely abolished in OVA-challenged DGKζ KO compared to WT mice (Fig. 2.3, A).
In contrast to our in vitro data, OVA-challenged DGKζ KO mice did not display a shift
towards a heightened Th1 response, since no difference in BAL IFNγ or OVA-specific
IgG2a serum antibody levels was observed compared to WT controls (Fig. 2.3, C and
D).
Although DGKζ is the predominant isoform that controls DAG-mediated signaling
in T cells, another DGK isoform known as DGKα also contributes to this process (170).
DGKα KO T cells displayed an enhancement of Th1 differentiation and a partial but
significant attenuation of Th2 differentiation when stimulated through their TCR and
expanded in vitro (Fig. 2.4, A and B). In accordance, DGKα KO mice showed a partial
but significant reduction in OVA-induced AHR and airway inflammation compared to WT
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controls (Fig. 2.4, C-F). Thus, the manipulation of DAG signaling by targeting DGK
enzymes attenuates OVA-induced allergic asthma.
Protection from OVA-induced airway inflammation and AHR in the absence of DGKζ is
independently mediated by separate compartments
The near complete abolition of AHR in DGKζ KO mice despite a significant but partial
reduction in airway inflammation prompted us to test whether DGKζ deficiency in nonhematopoietic cells also contributed to protection against OVA-induced allergic asthma.
The hematopoietic compartment of lethally irradiated WT and DGKζ KO mice was
reconstituted with bone marrow cells from either WT or DGKζ KO mice. Similar to DGKζ
KO mice, DGKζ KOàDGKζ KO BM chimeric mice showed reduction in eosinophilic
inflammation, Th2 cytokine levels in the BAL fluid, and AHR responses compared to
WTàWT BM chimeric mice. Surprisingly, however, we found that the reduction in
inflammation and AHR was mediated by two separate cell compartments. While WT
mice reconstituted with DGKζ KO bone marrow cells displayed significantly reduced
eosinophilic inflammation and Th2 cytokine levels in the BAL fluid, they were not
protected against OVA-induced AHR (Fig. 2.5, A-C). In contrast, DGKζ KO mice
reconstituted with WT bone marrow cells were completely protected from OVA-induced
AHR despite the presence of eosinophilic inflammation and Th2 cytokines in the BAL
fluid (Fig. 2.5, A-C). These data suggested that DGKζ deficiency in hematopoietic cells
contributes to reduced airway inflammation, while DGKζ deficiency in non-hematopoietic
cells leads to protection against AHR.
DGKζ deficiency in T cells protects from OVA-induced airway eosinophilia and partially
attenuates OVA-induced Th2 differentiation
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To more precisely interrogate the impact of DGKζ deficiency in hematopoietic cells in
OVA-induced airway inflammation, DGKζ was conditionally deleted in hematopoietic
cells or T cells using a Vav-inducible Cre (Vav-Cre DGKζfl/fl mice) or CD4-inducible Cre
(CD4-Cre DGKζfl/fl mice), respectively. Vav-Cre DGKζfl/fl mice displayed significantly
attenuated OVA-induced eosinophil accumulation and IL-4 levels in the BAL fluid, while
the OVA-induced AHR response was completely intact (Fig. 2.5, D-F). Similarly, CD4Cre DGKζfl/fl mice showed a significant reduction in OVA-induced eosinophil
accumulation and IL-4 levels in the BAL fluid (Fig. 2.5, G and H).
Interestingly, while IL-4 levels were diminished in Vav-Cre DGKζfl/fl and CD4-Cre
DGKζfl/fl mice following OVA challenge, IL-5 and IL-13 levels were relatively intact in
these mice (Fig. 2.5, F and H). To test if the loss of DGKζ in T cells selectively
attenuated the ability of T cells to produce IL-4 after Th2 differentiation in vivo, we
adoptively transferred a mixture of CD45.1+CD45.2+ WT and CD45.2+ DGKζ KO OT-II
CD4+ T cells into naïve CD45.1+ WT mice followed by OVA immunization. OT-II T cells
express a transgenic T cell receptor specific for the OVA323-339 peptide presented on the
MHC Class II I-Ab molecule. In accordance with the Vav-Cre DGKζfl/fl and CD4-Cre
DGKζfl/fl data, we found that the proportion of DGKζ KO OT-II T cells expressing IL-4 was
significantly diminished while the proportions of DGKζ KO OT-II T cells expressing IL-5
and IL-13 was relatively unaltered compared to WT OT-II T cells following OVA
sensitization (Fig. 2.5, I). These data suggest that the loss of DGKζ selectively impairs
the ability of T cells to produce IL-4 in a T cell-intrinsic manner during Th2 differentiation
in vivo. In addition, we observed that the frequency of DGKζ KO OT-II T cells expressing
IFNg was significantly increased compared to WT OT-II T cells following OVA
sensitization, suggesting that Th1 differentiation was enhanced in the absence of DGKζ
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in vivo (Fig. 2.5, I). Overall, these data demonstrate that DGKζ deficiency inhibits the
development of eosinophilic airway inflammation independently of AHR in a T cellintrinsic manner by partially attenuating Th2 differentiation in vivo.
DGKζ deficiency in airway smooth muscle cells protects from OVA-induced AHR
Airway hyperresponsiveness is regulated indirectly in part by the production of
contractile mediators from sensory neurons that innervate the lungs, and directly by
contraction of airway smooth muscle cells driven by the activation of receptors, such as
muscarinic type 3 (M3) receptors, that bind to these mediators (177-179). Furthermore,
DGKζ has been shown to be expressed in sensory neurons arising from the dorsal root
ganglion and in smooth muscle cells (180-184). To identify the non-hematopoietic cell
type that was responsible for protection against OVA-induced AHR in the absence of
DGKζ, DGKζ was conditionally deleted in sensory neurons (Pirt-Cre DGKζfl/fl) and
smooth muscle cells (Myh11-Cre DGKζfl/fl). Pirt-Cre DGKζfl/fl mice exhibited similar OVAinduced AHR compared to control mice (Fig. 2.6, A). However, Myh11-Cre DGKζfl/fl mice
were protected from OVA-induced AHR, despite unaltered airway inflammation (Fig. 2.6,
B-D). Moreover, tracheal rings isolated from either DGKζ KO or Myh11-Cre DGKζfl/fl mice
displayed significantly attenuated methacholine-induced contractile forces as compared
to WT or Myh11-Cre controls (Fig. 2.6, E-G). These data demonstrate that DGKζ
regulates airway smooth muscle cell contraction in a cell-intrinsic manner to promote
allergen-induced AHR independently of inflammation.
Enhancement of ERK signaling in T cells is sufficient to protect from OVA-induced
allergic airway inflammation but insufficient to protect from OVA-induced AHR
We next tested whether increased ERK signaling was responsible for the effect of DGKζ
deficiency on Th2 differentiation. To this end, we assessed Th differentiation of naïve
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DGKζ KO CD4+ T cells activated through their TCR in the presence of the U0126, a
pharmacological inhibitor of MEK1/2 (the kinase that phosphorylates and activates
ERK). Indeed, we found that inhibition of ERK signaling was sufficient to restore Th2
differentiation in DGKζ KO T cells (Fig. 2.7, A). In addition, while treatment with U0126
did not alter the frequency of IL-4 and IL-13-producing WT T cells, inhibition of ERK
signaling increased the frequency of WT T cells producing IL-5 (Fig. 2.7, A). In contrast,
Th1 differentiation in WT and DGKζ KO T cells was attenuated in the presence of
U0126, thus establishing that enhanced TCR-mediated DAG signaling impairs Th2
differentiation and promotes Th1 differentiation in an ERK-dependent manner (Fig. 2.7,
A).
We next took a gain-of-function approach to test whether the enhancement of
ERK signaling in T cells was sufficient to attenuate OVA-induced airway inflammation.
Sevenmaker (ERKSEM) transgenic mice express a transgene that encodes a gain of
function mutant of Erk2 driven from the human CD2 promoter and locus control region,
which results in selective enhancement of the ERK signaling pathway specifically in T
cells (121). Similar to DGKζ KO T cells, ERKSEM T cells displayed enhanced Th1
differentiation and attenuated Th2 differentiation following TCR stimulation and
expansion in vitro (Fig. 2.7, B and C). Furthermore, ERKSEM mice displayed significantly
reduced eosinophilia and Th2 cytokine release in the airways following OVA challenge
compared to WT controls, thus demonstrating that the enhancement of ERK signaling is
sufficient to inhibit Th2 differentiation and protect from OVA-induced airway inflammation
in vivo (Fig. 2.7, E and F). Importantly, similar to the Vav-Cre DGKζfl/fl mice, ERKSEM mice
displayed intact OVA-induced AHR compared to WT controls despite attenuated OVAinduced type 2 airway inflammation (Fig. 2.7, D). Overall, these data demonstrate that
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the regulation of DAG signaling by DGKζ controls Th2 differentiation in an ERKdependent manner in T cells to promote OVA-induced airway inflammation
independently of AHR.
Pharmacological inhibition of DGK is sufficient to protect from OVA-induced asthma
We next tested whether DGK could represent a novel target for the prevention and
treatment of asthma. While there are no known selective and potent inhibitors of DGKζ,
a pan-DGK inhibitor, R59949 that is relatively selective for DGKa is commercially
available (185, 186). DGKa and DGKζ are expressed in both T cells and smooth muscle
cells (170, 171, 182). Since DGKa KO mice have a partial but significant reduction in
OVA-induced airway inflammation and AHR, we tested whether pharmacological
inhibition of DGKa kinase activity by R59949 could block OVA-induced type 2 airway
inflammation and AHR. Mice were systemically treated with R59949 during the late
sensitization and airway challenge phases of the murine model of OVA-induced asthma.
Compared to vehicle-treated mice, R59949-treated mice displayed significantly
attenuated AHR, and reduced eosinophilia and Th2 cytokines in the BAL fluid (Fig. 2.8,
A-C). To test whether DGKa inhibition could block type 2 airway inflammation and AHR
after allergen-specific T cell responses have already been established, OVA-sensitized
mice were systemically treated with R59949 only during the airway challenge phase of
the OVA-induced asthma model. Compared to vehicle-treated mice, R59949-treated
mice again exhibited significantly reduced OVA-induced AHR (Fig. 2.8, D). In contrast,
treatment with R59949 during the airway challenge phase failed to alter type 2 airway
inflammation following OVA challenge (Fig. 2.8, E and F). Together, these data suggest
that DGK can be pharmacologically targeted to reduce AHR and airway inflammation.
However, while the acute administration of a DGK inhibitor is sufficient to attenuate
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OVA-induced AHR, the DGK inhibitor must be administered during the sensitization
stage to inhibit the type 2 airway inflammation.
To further examine the therapeutic potential of targeting DGK, we tested whether
inhibition of DGKa by R59949 affects human airway smooth muscle contraction. Human
airway smooth muscle cells were pre-treated with or without R59949 and stimulated with
the non-selective M3 receptor agonist, carbachol. The phosphorylation of myosin light
chain (MLC), a critical step in smooth muscle cell contraction, was reduced by R59949
(Fig. 2.8, G). To test whether this effect translated to the attenuated contraction of
human airways, precision cut lung slices (PCLS) were obtained from lung transplant
donors and treated with R59949. Following overnight incubation with R59949,
carbachol-induced bronchoconstriction was significantly decreased (Fig. 2.8, H). Overall,
these data highlight that acute inhibition of DGK is sufficient to protect from the
development of OVA-induced airway inflammation and AHR and is sufficient to attenuate
OVA-induced AHR in presensitized mice, suggesting that DGK is a potential therapeutic
target for the prevention and treatment of asthma.
Discussion
Our findings demonstrate that the regulation of diacylglycerol signaling by DGKζ and
DGKa plays a critical role in a mouse model of allergen-induced asthma. Genetic
ablation of DGKζ or DGKa resulted in protection from OVA-induced airway inflammation
and AHR. Using bone marrow chimeras, we demonstrated that the attenuation of AHR is
due to the loss of DGKζ in the radioresistant compartment while the reduction of airway
inflammation is due to the loss of DGKζ in the radiosensitive compartment, thus
highlighting that DGKζ regulates these processes in separate compartments and
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independently of each other. Generation of cell-type specific conditional DGKζ KO mice
revealed that the protection from OVA-induced airway inflammation was mediated by the
loss of DGKζ in T cells, while the attenuation of OVA-induced AHR was facilitated by the
absence of DGKζ in airway smooth muscle cells. Finally, acute loss of DGK activity
through pharmacological blockade with a DGKa inhibitor was sufficient to protect from
the induction of murine allergen-induced asthma, attenuate allergen-induced AHR in
mice with established allergen-induced immune responses, and reduce carbacholinduced bronchoconstriction of human airways, thus establishing that modulating DGK
activity represents a viable therapeutic strategy for the treatment of asthma.
Given that DAG acts as a positive signal transduction molecule downstream of
activating receptors, one might predict that the inhibition of DGK would always lead to an
enhancement of immune responses. Our findings highlight the idea that augmenting
DAG-mediated signaling does not necessarily lead to increased activation. In settings of
Th1 and cell-mediated immune responses, increased DAG signaling caused by the loss
of DGKζ augments the function of T cells and NK cells (171-174). In contrast, mast cell
degranulation during allergic responses is inhibited in the absence of DGKζ (175). Thus,
targeting DGKζ is immunomodulatory, i.e., it is immunostimulatory or
immunosuppressive depending on the context. Our data presented here reinforce this
notion, as the loss of DGKζ inhibits Th2-mediated inflammation.
We demonstrated that the loss of DGKζ attenuated the differentiation of naïve T
cells into Th2 phenotype in vitro and suppressed eosinophilic inflammation and Th2
cytokine release in the BAL fluid of asthmatic mice in vivo. Although DGKζ KO mice
displayed a reduction in the BAL levels of all major Th2 cytokines (IL-4, IL-5, and IL-13),
only IL-4 but not IL-5 or IL-13 was reduced in the airways of Vav-Cre DGKζfl/fl and CD440

Cre DGKζfl/fl mice. In accordance, DGKζ KO OT-II cells displayed a selective impairment
in their potential to produce IL-4 but not IL-5 or IL-13 compared to co-transferred WT
OT-II cells following OVA sensitization in vivo. These results suggest that the loss of
DGKζ selectively impairs the ability of T cells to produce IL-4 in a T cell-intrinsic manner
during Th2 differentiation in vivo. This could potentially explain the selective reduction in
BAL IL-4 levels seen in the hematopoietic-specific and T cell-specific DGKζ KO mice
following OVA challenge in vivo. It is still unclear why WT mice reconstituted with DGKζ
KO bone marrow cells showed a reduction in all three Th2 cytokines. The bone marrow
reconstitution studies may need to be interpreted with caution given the unknown effects
of irradiation, reconstitution efficiency, and increased age of bone marrow-transplanted
mice on asthma.
The signaling mechanism by which DGK deficiency protects against asthma is
not entirely clear. We started our studies by hypothesizing that DGK deficiency would
attenuate Th2 differentiation by enhancing ERK phosphorylation. We observed that
partial attenuation of ERK signaling by U0126 restored Th2 differentiation in DGKζ KO T
cells. Furthermore, T cells from ERKSEM mice showed increased Th1 and decreased Th2
differentiation in vitro, which correlated with protection from OVA-induced type 2 airway
inflammation in vivo. Thus, the effect of DGKζ deficiency on the inhibition of Th2
differentiation is dependent on increased ERK activation. However, the mechanism by
which DGK affects acetylcholine-induced smooth muscle cell contraction is still unclear.
Similar to TCR signaling, activation of muscarinic type 3 receptors, which are GPCRs
that signal through Gaq proteins, leads to PLC-dependent DAG generation and ERK
activation (187, 188). Thus, it is possible that the attenuation of smooth muscle
contraction in DGKζ KO airway smooth muscle cells is also ERK-dependent. However,
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previous work has shown that ERK signaling promotes rather than suppresses
carbachol-induced contraction in ileal smooth muscle cells and a1-adrenergic receptorinduced contraction, which is another Gaq-coupled GCPR, in vascular smooth muscle
cells (189, 190). Interestingly, previous studies have shown that a rise in intracellular
Ca2+ initiated by PLC critically mediates the crossbridge cycling of actin and myosin to
drive smooth muscle contraction and DAG maintains contraction by inhibiting a negative
regulator of the crossbridge cycling (191-193). Consequently, one might expect that the
lack of DGKζ would exacerbate bronchoconstriction. However, the diminution of smooth
muscle contraction by the loss of DGKζ suggests that other biological mechanisms are
involved.
Importantly, our study demonstrates that AHR and eosinophilic airway
inflammation are separate and distinct processes that mediate the development of
asthma and can exist independently of each other. In accordance, recent clinical trials
have shown that while inhibition of type 2 cytokine signaling is efficacious in reducing
eosinophilia and decreasing the frequency of asthma exacerbations in asthmatic
patients, these approaches failed to alter impaired baseline lung function and histamineinduced airway responses, thus implying that suppressing inflammation is not sufficient
to reverse AHR and airway smooth muscle dysfunction in asthma (194, 195). Our
findings formally demonstrate the novel concept that airway eosinophilic inflammation
and AHR are regulated independently of each other and reveal that DGKζ plays a
central role in the induction of these processes during the development of asthma. We
envision targeting DGKζ as a novel therapeutic strategy that will promote the prevention
and resolution of asthma by suppressing both the immune and non-immune responses
that drive the disease.
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Figures

Figure 2.1. Conventional CD4+ T cells produce IL-4 following TCR activation to
drive Th2 differentiation under nonpolarizing conditions in vitro. (A), Frequency of
cytokine-producing and GATA3-expressing WT CD4+ T cells after activation with antiCD3 and anti-CD28 in the presence of irradiated WT CD4-depleted splenocytes
(nonpolarizing conditons) for 5 days in vitro. (B), Frequency of cytokine-producing and
(C), GATA3-expressing WT and STAT6 KO CD4+ T cells after activation with anti-CD3
and anti-CD28 under nonpolarizing conditions for 5 days in vitro. (D), Frequency of
cytokine-producing WT CD4+ T cells after activation with anti-CD3 and anti-CD28 in the
presence of media alone, anti-IL-4 antibody, or TH2 (anti-IL12 + anti-IFNg + IL-4)
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conditions for 5 days in vitro. (E), Frequency of cytokine-producing and GATA3expressing WT or IL-4 KO CD4+ T cells after activation with anti-CD3 and anti-CD28 in
the presence of either irradiated WT or IL-4 KO CD4-depleted splenocytes for 5 days in
vitro. Data are representative of at least 3 independent experiments.

44

Figure 2.2. DGKζ KO T cells display impaired Th2 differentiation in vitro. (A),
Frequency of cytokine-producing and (B), GATA3-expressing WT and DGKζ KO CD4+ T
cells after activation with anti-CD3 and anti-CD28 under nonpolarizing conditions for 5
days in vitro. (C), Frequency of cytokine-producing WT and DGKζ KO CD4+ T cells after
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activation with anti-CD3 and anti-CD28 under nonpolarizing conditions in the absence or
presence of exogenous IL-4 for 5 days in vitro. (E-G), Frequency of cytokine-producing
and (H), GATA3-expressing WT and DGKζ KO CD4+ T cells untreated or treated with
exogenous IL-4 at various timepoints following activation with anti-CD3 and anti-CD28
under nonpolarizing conditions for 5 days in vitro. Data are pooled from 5 independent
experiments (A and B) or representative of 2 independent experiments (C-H). Data are
represented as mean ± SEM; * P < 0.05, ** P < 0.01, **** P < 0.0001, NS = not
significant [two-sided unpaired Student’s t-test, (C) and (D); Two way ANOVA with
Bonferroni’s post-test, (A); One way ANOVA with Tukey’s post-test, (B) and (E)].
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Figure 2.3. DGKζ KO mice are protected from OVA-induced allergic airway
inflammation and airway hyperresponsiveness (AHR). (A), Changes in lung
resistance after methacholine challenge and (B), total number of eosinophils (Eos),
macrophages (Mac), lymphocytes (Lym), and neutrophils (Neu) in the bronchoalveolar
lavage (BAL) fluid of unchallenged or OVA-challenged WT and DGKζ KO mice [(A), n =
6-9 mice/group; (B), n = 6 mice/unchallenged group, n = 19-22 mice/challenged group);
done in collaboration with Wen Lu and Amanda Schmidt Paustian]. (C) and (D), BAL
fluid Th1 and Th2 cytokine levels and OVA-specific IgG1 and IgG2a serum antibody
levels in OVA-challenged WT and DGKζ KO mice [(n = 14-16 mice/group); data in (C)
was done in collaboration with Wen Lu and Amanda Schmidt Paustian]. (E),
Representative images (at 20x magnification) and compiled histopathological scores of
hematoxylin and eosin (H&E) staining of unchallenged or OVA-challenged WT and
DGKζ KO mice (n = 4-5 mice/group). (A) through (C) was done in collaboration with Wen
Lu and Moyar Ge. Data are pooled from at least 2 independent experiments and
represented as mean ± SEM; * P < 0.05, ** P < 0.01, **** P < 0.0001, NS = not
significant [two-sided unpaired Student’s t-test, (C) and (D); Two way ANOVA with
Bonferroni’s post-test, (A); One way ANOVA with Tukey’s post-test, (B) and (E)].
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Figure 2.4. DGKα KO mice are partially protected from OVA-induced allergic
airway inflammation and AHR. (A and B), Frequency of cytokine-producing WT and
DGKa KO CD4+ T cells after activation with anti-CD3 and anti-CD28 under nonpolarizing
conditions for 5 days in vitro (n = 11 mice/group). C, Changes in lung resistance in
response to methacholine, (D), Total number of eosinophils (Eos), macrophages (Mac),
lymphocytes (Lym), and neutrophils (Neu), and (E), bronchoalveolar lavage (BAL) fluid
Th2 cytokine levels in OVA-challenged WT and DGKα KO [(C), n = 10 mice/group; (D), n
= 15-17 mice/group; (E), n = 13-14 mice/group]. (F), OVA-specific IgG1 and IgG2a
serum antibody levels in OVA-challenged WT and DGKζ KO mice (n = 13-14
mice/group). (A) through (F) was done in collaboration with Wen Lu and Moyar Ge. Data
are pooled from at least 3 independent experiments and represented as mean ± SEM; *
P < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant [Two way ANOVA with
Bonferroni’s post-test, (C); two-sided paired Student’s t-test, (B); two-sided unpaired
Student’s t-test, (D) through (F)].
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Figure 2.5. Hematopoietic and non-hematopoietic cells differentially contribute to
OVA-induced airway inflammation and AHR in the absence of DGKζ. (A), Changes
in lung resistance in response to methacholine challenge and (B and C),
bronchoalveolar lavage (BAL) cell counts [total (Tot), eosinophils (Eos), macrophages
(Mac), lymphocytes (Lym), and neutrophils (Neu)], and BAL cytokine levels of OVAchallenged WT and DGKζ KO BM chimeras (n = 7-9 mice/group). (D-F), Changes in
lung resistance following methacholine challenge, BAL cell counts, and BAL cytokine
levels in OVA-challenged Vav-Cre DGKζfl/fl mice and Vav-Cre controls [(D), n = 7
mice/group; (E and F), n = 13-14 mice/group]. (G and H), BAL cell counts and BAL
cytokine levels in OVA-challenged CD4-Cre DGKζfl/fl mice and CD4-Cre controls [(G), n
= 12-13 mice/group; (H), n = 16-17 mice/group]. (I), Representative flow cytometry plots
and KO/WT ratios of adoptively transferred cytokine-producing WT OT-II and DGKζ KO
OT-II CD4+ T cells (pregated on CD4+Vb5+ live singlets) in the spleen of OVA-sensitized
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congenically disparate WT hosts following restimulation with PMA/ionomycin ex vivo (n =
10 mice/group). (A) through (H) was done in collaboration with Wen Lu, Moyar Ge, and
Amanda Schmidt Paustian. Data are pooled from at least 2 independent experiments
and represented as mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001, NS = not
significant [Two way ANOVA with Bonferroni’s post-test, (A) and (D); One way ANOVA
with Tukey’s post-test, (B); One way ANOVA with Dunn’s post-test, (C); two-sided
unpaired Student’s t-test, (E) through (H); one-sided Student’s t-test, (I)].
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Figure 2.6. The loss of DGKζ in airway smooth muscle cells protects against AHR.
(A and B), Changes in lung resistance in response to methacholine challenge of OVAchallenged Pirt-Cre DGKζfl/fl, Myh11-Cre DGKζfl/fl, and their respective WT control mice
[(A), n = 8-11 mice/group; (B), n = 9-14 mice/group, (A) and (B) was done in
collaboration with Nadan Wang and Deepak Deshpande]. (C), Total number of
eosinophils (Eos), macrophages (Mac), lymphocytes (Lym), and neutrophils (Neu), and
(D), Th2 cytokine levels in bronchoalveolar lavage (BAL) fluid of OVA-challenged
Myh11-Cre DGKζfl/fl mice and DGKζfl/fl controls (n = 18-21 mice/group). (E-G), Contractile
forces generated from DGKζ KO, Myh11-Cre DGKζfl/fl, Myh11-Cre and DGKζfl/fl control
tracheal rings in response to methacholine [n = 6-11 mice/group, done in collaboration
with Deepak Deshpande]. Data are pooled from at least 2 independent experiments and
represented as mean ± SEM; * P < 0.05, ** P < 0.01, NS = not significant [Two way
ANOVA with Bonferroni’s post-test, (A), (B), (E) through (G); two-sided unpaired
Student’s t-test, (C) and (D)].
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Figure 2.7. Enhancement of ERK signaling in T cells is sufficient to protect from
OVA-induced allergic airway inflammation but insufficient to protect from OVAinduced AHR. (A), Frequency of cytokine-producing WT and DGKζ KO CD4+ T cells or
(B and C), WT and sevenmaker transgenic (ERKSEM) CD4+ T cells after pretreatment
with either vehicle control or U0126 followed by activation with anti-CD3 and anti-CD28
under nonpolarizing conditions for 5 days in vitro [(A), n = 3 mice/group; (B and C), n = 6
mice/group]. (D-F), Changes in lung resistance following methacholine challenge,
bronchoalveolar lavage (BAL) cell counts [total (Tot), eosinophils (Eos), macrophages
(Mac), lymphocytes (Lym), and neutrophils (Neu)], and BAL Th2 cytokine levels in OVAchallenged WT and ERKSEM mice [(D), n = 8-9 mice/group; (E and F), n = 21-26
mice/group]. Data are representative of 2 independent experiments (A) or pooled from at
least 2 independent experiments (C-G). (D) was done in collaboration with Nadan Wang
and Deepak Deshpande. Data are represented as mean ± SEM; * P < 0.05, ** P < 0.01,
*** P < 0.001, NS = not significant [two-sided unpaired Student’s t-test, (A), (E), and (F);
Two way ANOVA with Bonferroni’s post-test, (D); two-sided paired Student’s t-test, (C)].
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Figure 2.8. Pharmacological inhibition of diacylglycerol kinase (DGK) protects
against OVA-induced allergic airway inflammation and AHR. (A-C), Changes in lung
resistance following methacholine challenge, bronchoalveolar lavage (BAL) cell counts
[Total (Tot), eosinophils (Eos), macrophages (Mac), lymphocytes (Lym), and neutrophils
(Neu)], and BAL cytokine levels in OVA-challenged mice treated with either vehicle
control or R59949 during late sensitization/airway challenge phase or (D-F), or treated
with either vehicle control or R59949 only during the airway challenge phase of the OVAinduced asthma model [(A), n = 7-8 mice/group, done in collaboration with Moyar Ge;
(B), n = 15-17 mice/group; (C), n = 10-11 mice/group; (D-F), n = 8-10 mice/group, (D)
was done in collaboration with Nadan Wang and Deepak Deshpande]. (G), Western
blotting of phospho-myosin light chain (pMLC), phospho-protein kinase B (pAkt), and
phospho-myosin phosphatase target subunit 1 (pMYPT1) in lysates of carbacholstimulated human airway smooth muscle (HASM) cells pretreated with vehicle vs.
R59949 [n = 3 donors, done in collaboration with Cynthia Koziol-White from the lab of
Reynold Panettieri Jr.]. (H), Carbachol-induced bronchoconstriction of human precision
cut lung slices (PCLS) pretreated with vehicle vs. R59949 [n = 9-23 slices/condition from
3-7 donors/condition; done in collaboration with Cynthia Koziol-White from the lab of
Reynold Panettieri Jr.]. Data are pooled from at least 2 independent experiments and
represented as mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, NS
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= not significant [Two way ANOVA with Bonferroni’s post-test, (A); two-sided unpaired
Student’s t-test, (B) through (E)].
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CHAPTER 3: DIACYLGLYCEROL KINASE ZETA REGULATES PAPAIN-INDUCED
TYPE 2 AIRWAY INFLAMMATION
Introduction
Asthma is a chronic respiratory disease that is characterized by airway
inflammation and obstruction that is initiated at mucosal surfaces where inhaled
allergens contact the lung epithelium. While common allergens, such as house dust mite
(HDM), papain, and Alternaria alternata, are heterogeneous, a common component of
these allergens are molecules with protease activity. Proteases in inhaled allergens
damage the epithelial barrier and trigger the production of IL-25, IL-33, and TSLP by
cells residing in the epithelium (196-199). These epithelial-derived cytokines activate
tissue resident immune cells, which include group 2 innate lymphoid cells (ILC2) that
produce IL-5 and IL-13, basophils that produce IL-4, and mast cells that release
vasoactive amines and inflammatory lipid mediators (200-205). These epithelial-derived
cytokines further prime lung dendritic cells to process antigen, migrate to the draining
lymph nodes, and activate allergen-specific CD4+ T cells (206).
Inhalation of papain, a plant-derived cysteine protease, has been shown to cause
occupational asthma in humans (207). Intranasal administration of papain in mice
triggers the activation of ILC2s and the induction of airway eosinophilia in the airways in
an IL-33-dependent manner (200). Damage elicited by the protease activity of papain
can lead to necrosis of IL-33-expressing cells, resulting in the release of bioactive IL-33
stored in the nucleus into the extracellular milieu. However, cell death-independent
mechanisms for IL-33 release can occur in response to extracellular ATP and
mechanical stress (208, 209). While the enzymatic activity of papain has been shown to
be important for the initiation of type 2 immune responses in the lung, the molecular
signals that regulate the sensing of protease allergen-derived enzymatic activity by the
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epithelial barrier in the airways to trigger the release of IL-33 to elicit ILC2-mediated
inflammation are not completely understood.
Diacylglycerol kinases (DGK) are a family of enzymes that convert diacylglycerol
(DAG) to phosphatidic acid (PA) via phosphorylation to terminate DAG-mediated
signaling (64, 73). There are 10 different isoforms comprising 5 different classes of
DGKs, each of which control different cellular functions based on their distinct structural
motifs and subcellular localization (64, 73-76). The zeta isoform of DGK (DGKζ) is widely
expressed in the hematopoietic and non-hematopoietic compartments and is important
for regulating diverse cellular processes in both of these compartments (176). In the
previous chapter, we demonstrated that DGKζ plays an immunomodulatory role in type 2
immune responses by positively controlling Th2 differentiation through the regulation of
TCR-mediated ERK signaling to promote type 2 airway inflammation. Furthermore, the
loss of DGKζ has been shown to attenuate FceRI-mediated degranulation of mast cells
and consequently, DGKζ KO mice display impaired IgE-mediated anaphylactic
responses in vivo (132). However, whether DGKζ plays an immunomodulatory role in
ILC2-mediated inflammatory responses is unknown.
Here, we report that the loss of DGKζ protects from papain-induced type 2 airway
inflammation. Papain-challenged DGKζ KO displayed reduced ILC2 accumulation,
decreased IL-5 and IL-13 release, and attenuated eosinophilia in the airways.
Unexpectedly, protection from papain-induced airway inflammation was not due to the
loss of DGKζ in the hematopoietic compartment because hematopoietic-specific DGKζ
KO mice exhibited intact papain-induced type 2 airway inflammation. Interestingly, IL-33mediated inflammation was also intact in DGKζ KO mice, suggesting that the impairment
in papain-mediated airway inflammation is not due to defective responses to IL-33 in
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DGKζ KO mice. However, we found that IL-33 mRNA levels were significantly lower in
DGKζ KO mice and this correlated with decreased frequencies of IL-5-producing lung
ILC2s at homeostasis. Yet, conditional loss of DGKζ in alveolar type II cells , sensory
neurons, or smooth muscle cells did not recapitulate the protection from papain-induced
airway inflammation seen in global DGKζ KO mice, suggesting that DGKζ controls the
regulation of IL-33 through an unknown non-hematopoietic cell type.
Results
DGKζ KO mice are protected from papain-induced type 2 airway inflammation
In the previous chapter, we demonstrated that DGKζ controls Th2 differentiation
in vitro and promotes the generation of Th2 cells to drive OVA-induced airway
inflammation in vivo. We wanted to examine whether DGKζ also controlled the
generation and function of ILC2s in the lung. To test this, lung ILC2s were isolated and
characterized from naïve DGKζ KO mice. While total numbers and GATA3 expression in
lung ILC2s were normal in DGKζ KO mice, DGKζ KO lung ILC2 displayed significantly
impaired ability to produce IL-5 and IL-13 following ex vivo stimulation with PMA and
ionomycin (Fig. 3.1 and Fig. 3.2, A). To test if ILC2-mediated inflammatory responses
were impaired in DGKζ KO mice, WT and DGKζ KO mice were subjected to a mouse
model of acute allergen-induced airway inflammation elicited by intranasal administration
of papain for 5 consecutive days. In line with our in vitro data, papain-challenged DGKζ
KO exhibited significantly reduced ILC2 accumulation in the bronchoalveolar lavage
(BAL) fluid and the lung parenchyma (Fig. 3.2, B). Furthermore, proliferation of lung
ILC2s in response to papain was diminished in DGKζ KO mice as determined by
decreased frequency and total number of Ki67+ lung ILC2s (Fig. 3.2, C). Additionally, we
observed a decreased frequency of IL-5+IL-13+ ILC2s in papain-challenged DGKζ KO
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mice, implying that ILC2 cytokine effector function in response to papain was diminished
in DGKζ KO mice (Fig. 3.2, D). This correlated with decreased BAL Th2 cytokine levels
in the lungs of papain-challenged DGKζ KO mice (Fig. 3.2, E). Production of IL-5 and IL13 by ILC2 is critical for early eosinophil recruitment and activation into the airways and
the lung parenchyma following intranasal papain administration (200). Indeed, papainchallenged DGKζ KO mice displayed reduced accumulation of eosinophils the BAL and
lung parenchyma (Fig. 3.2, F). Overall, the loss of DGKζ attenuates papain-induced type
2 airway inflammation.
Protection from papain-induced airway inflammation in the absence of DGKζ is not
mediated by the hematopoietic compartment.
The initiation of type 2 immune responses by intranasal administration of papain is
mediated by cellular responses from both the hematopoietic and non-hematopoietic
compartments. To test if DGKζ deficiency in the hematopoietic cells was sufficient to
provide protection from papain-induced airway inflammation, DGKζ was conditionally
deleted in hematopoietic cells using a Vav-inducible Cre (Vav-Cre DGKζfl/fl mice). To our
surprise, Vav-Cre DGKζfl/fl mice displayed intact papain-induced eosinophilia in the
airways and in the lung parenchyma (Fig. 3.3, A). Furthermore, accumulation of lung
ILC2s in response to papain was unchanged while the accumulation of ILC2s in the BAL
was significantly enhanced in Vav-Cre DGKζfl/fl mice (Fig. 3.3, B). Moreover, the
induction of BAL Th2 cytokines in the airway of hematopoietic-specific conditional DGKζ
KO mice was intact and slightly enhanced following papain exposure (Fig. 3.3, C). These
data suggested that protection from papain-induced airway inflammation was not driven
by loss of DGKζ in the hematopoietic compartment but rather due to loss of DGKζ in the
non-hematopoietic compartment.
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Airway inflammation driven by intranasal administration of IL-33 is intact in DGKζ KO
mice
Tissue-derived cytokines, IL-33 and TSLP, have been shown to be released from
epithelial cells in response to papain in vitro and in vivo (200, 210-212). However,
papain-induced eosinophilic inflammation is largely dependent on IL-33 in vivo (205,
211). Indeed, papain-induced influx of eosinophils, ILC2 accumulation, and Th2 cytokine
release in the airways was almost completely abrogated in mice lacking the IL-33
receptor, ST2, but remained relatively intact in TSLPR KO mice, thus confirming that
papain-induced eosinophilic inflammation is predominantly mediated by IL-33 (Fig. 3.4,
A-C). To test if protection from papain-induced airway inflammation in the absence of
DGKζ was due to impaired responses to IL-33, DGKζ KO mice were subjected to
intranasal administration of IL-33 for 3 consecutive days. In contrast to the papain
treatment, DGKζ KO exhibited similar accumulation of eosinophils and ILC2s in the BAL
following IL-33 treatment compared to control mice (Fig. 3.4, D and E). In addition, IL-33mediated accumulation of lung eosinophils and ILC2s was enhanced in DGKζ KO mice
compared to WT controls (Fig. 3.4, D and E). However, BAL IL-5 and IL-13 levels in
DGKζ KO mice following IL-33 administration was comparable to levels seen in WT
controls (Fig. 3.4, F). To further test if loss of DGKζ impacted responses to IL-33, ILC2s
were sorted from the lungs of naïve WT and DGKζ KO mice and stimulated with IL-33 in
combination with IL-2 for 72 hours. DGKζ KO exhibited similar production of IL-5 and IL13 in response to stimulation with IL-33 and IL-2 (Fig. 3.5, A). Furthermore, the
frequency of IL-5+ and IL-13+ DGKζ KO ILC2s in response to IL-33 stimulation following
in vitro expansion was comparable to responses from WT ILC2s (Fig. 3.5, B and C).
Overall, these data demonstrated that protection from papain-induced airway
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inflammation in DGKζ KO mice is not due to diminished responses to IL-33 released
following papain challenge.
Loss of DGKζ in alveolar type II cells does not protect from papain-induced airway
inflammation
The induction of potent type 2 airway inflammation in response to IL-33 administration
but not to papain challenge in DGKζ KO mice suggested that the loss of DGKζ might be
affecting IL-33 expression, processing, or release. To test if the absence of DGKζ
impacted the regulation of lung IL-33 levels at homeostasis, we measured IL-33 mRNA
levels from whole lung homogenates obtained from naïve WT and DGKζ KO mice.
Surprisingly, we found significantly lower levels of IL-33 mRNA transcripts as well as
diminished levels of IL-25 and TSLP mRNA in DGKζ KO lungs compared to WT controls
(Fig. 3.6, A). Tissue-resident lung ILC2 constitutively produce IL-5 at homeostasis in a
manner that is partially dependent on IL-33 but not IL-25 or TSLP, implying the existence
of a homeostatic pool of IL-33 released in the absence of inflammation (213). We
observed that the frequency of DGKζ KO lung ILC2s producing IL-5 at homeostasis was
significantly decreased compared to WT controls, thus suggesting that homeostatic
release of IL-33 was potentially diminished in the absence of DGKζ (Fig. 3.6, B).
Alveolar type II cells are a predominant source of pulmonary IL-33 postnatally
and during adult life under homeostatic conditions (214). Furthermore, DGKζ has been
shown to be expressed in alveolar type II cells present in the lung epithelium (215). To
test if the loss of DGKζ in alveolar type II cells was sufficient to protect from papaininduced airway inflammation, DGKζ was conditionally deleted in alveolar type II cells
using the Nkx2.1-inducible Cre (Nkx2.1-Cre DGKζfl/fl mice). However, we found that
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papain-induced eosinophilia, ILC2 accumulation, and the induction of BAL Th2 cytokines
was unaltered in Nkx2.1-Cre DGKζfl/fl mice (Fig. 3.7, A-C).
Sensory neurons arising from the dorsal root ganglion (DRG) have been shown
to express the ST2 receptor and respond to IL-33 to produce neuropeptides, such
neuromedin U (NMU), that can promote ILC2 responses following infection with
Nippostronglus brasiliensis or during HDM-mediated type 2 inflammatory responses in
the lung (216-218). Additionally, airway smooth muscle cells have been shown to
express IL-33 mRNA transcript and potentially IL-33 protein that is upregulated during
asthmatic inflammation in vivo (219). To test if the loss of DGKζ in either of these cell
types was responsible for protection from papain-induced airway inflammation, DGKζ
was conditionally deleted in DRG sensory neurons using the Pirt-inducible Cre (Pirt-Cre
DGKζfl/fl) or in smooth muscle cells using the Myh11-inducible Cre (Myh11-Cre DGKζfl/fl).
However, similar to the Nkx2.1-Cre DGKζfl/fl mice, Pirt-Cre DGKζfl/fl and Myh11-Cre
DGKζfl/fl displayed comparable induction of eosinophils and ILC2 in the airways and the
lung parenchyma following papain challenge as compared to their respective Cre
controls (Fig. 3.7, D and E). Overall, these data indicate that DGKζ potentially regulates
papain-induced airway inflammation by regulating IL-33 levels in the lung during
homeostasis and inflammation but not directly through alveolar type II cells, DRG
sensory neurons, or airway smooth muscle cells.
Discussion
Our findings demonstrate that the regulation of diacylglycerol signaling by DGKζ plays a
critical role in a mouse model of protease-mediated allergic airway inflammation. Genetic
ablation of DGKζ resulted in protection from papain-induced type 2 airway inflammation.
Generation of hematopoietic-specific DGKζ KO mice revealed that protection from
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papain-induced airway inflammation was not due to the actions of DGKζ in the
hematopoietic compartment. Importantly, bypassing papain with administration of IL-33
elicited comparable inflammation in DGKζ KO mice compared to WT controls,
suggesting that the defect in type 2 immune responses mounted against papain is
upstream of IL-33 release. Indeed, DGKζ KO mice displayed significantly decreased IL33 mRNA levels, which correlated with decreased ILC2-mediated production of IL-5 at
homeostatic conditions in the lung. Surprisingly, the loss of DGKζ in alveolar type II cells,
DRG sensory neurons, or airway smooth muscle cells failed to protect from papaininduced ILC2 responses in vivo, suggesting that DGKζ is required in another cell type
from the non-hematopoietic lineage to regulate papain-induced airway inflammation.
As a negative regulator of DAG-mediated signaling, one might predict that the
loss of DGKζ would universally lead to immune activation. Interestingly, however, the
inhibition of DGKζ does not only enhance but also suppresses selective immune
responses. In settings of Th2 responses, increased DAG signaling suppresses the
degranulation of DGKζ KO mast cells resulting in protection from IgE-mediated
anaphylactic responses in vivo (132). Furthermore, augmenting TCR-mediated DAG
signaling impairs Th2 differentiation in DGKζ KO T cells through an ERK-dependent
manner to suppress OVA-induced airway inflammation in vivo. While these studies
demonstrate the role of DGKζ in type 2 immune cells, our data demonstrates that DGKζ
deficiency can also impair type 2 airway inflammation by potentially regulating the
function of the non-hematopoietic compartment to suppress ILC2 activation in the
airways. Overall, our data reinforces the notion that the loss of DGKζ inhibits Th2
inflammation through multiple mechanisms.
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The mechanism by which DGKζ protects from papain-induced airway
inflammation is not entirely clear. We began our studies by hypothesizing that DGKζ
would impact ILC2 function in a cell-intrinsic manner. However, ILC2 responses
following in vitro treatment with IL-33, the major effector cytokine released following
papain challenge, were relatively normal. Furthermore, deletion of DGKζ in the
hematopoietic compartment failed to provide protection from papain-induced airway
ILC2 accumulation and eosinophilia, suggesting that DGKζ regulates papain-induced
airway inflammation through an ILC2-extrinsic and non-hematopoietic manner. While we
observed that IL-33 mRNA levels were significantly diminished in DGKζ KO mice,
conditional deletion of DGKζ in alveolar type II cells, the predominant source of
pulmonary IL-33, failed to protect from papain-induced airway inflammation. These
results imply that either alveolar type II cells are not the relevant source of IL-33 for
potentiating papain-induced airway inflammation in vivo or DGKζ regulates IL-33 in
alveolar type II cells through an indirect mechanism by influencing the function of
secondary cell type, such a fibroblast or stromal cell, involved promoting papain-induced
IL-33 release. In agreement with the former, recent work has demonstrated that
adventitial stromal cells residing in adventitial cuff structures are sources of IL-33 and
TSLP in the lung airways and serve as a niche for tissue-resident ILC2s to help support
ILC2 responses during helminth infection in vivo (220). However, whether adventitial
stromal cells constitute the relevant source of pulmonary IL-33 to drive ILC2 activation in
response to papain and whether DGKζ regulates this response remains to be seen. The
mechanism by which papain elicits IL-33 release is not very well understood. Some
studies suggest that IL-33, which is constitutively stored in the nucleus, is primarily
released through necrosis of cells damaged by the protease activity of papain despite no
direct evidence of this process in vivo. Furthermore, IL-33 can be released through cell63

death independent mechanisms through either mechanical stress or ATP release (208,
209). Thus, it is also possible that papain enzymatic activity elicits IL-33 release from
alveolar type II cells or other IL-33 sources indirectly through mechanical sensing by
other cells, such as fibroblasts.
In summary, our study demonstrates that an enzyme involved in DAG
metabolism is important for protease-mediated airway inflammatory responses. Our data
suggest that DGKζ might function to regulate activation of the non-hematopoietic
compartment by papain enzymatic activity to prompt the release of IL-33 and initiate type
2 immune responses in the airways. We propose that DGKζ might represent a novel
target for the treatment of allergic airway inflammatory diseases driven by common
environmental proteases.
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Figures

Figure 3.1. Normal numbers and GATA3 expression of DGKζ KO lung ILC2s. (A),
Total numbers of type 2 innate lymphoid cells (ILC2) (gated on CD45+Lin-CD90.2+ST2+
live singlets with Lin- = CD3-CD5-CD11b-CD11c-CD19-B220-NK1.1-DX5-) from naïve WT
and DGKζ KO lungs (n = 9 mice/group). (B), Frequency of lung ILC2s (pregated on
CD45+Lin-CD90.2+ST2+ live singlets) expressing GATA3 from naïve WT and DGKζ KO
mice. (n = 9 mice/group). Data are pooled from 3 independent experiments and
represented as mean ± SEM; NS = not significant [two-sided unpaired Student’s t-test,
(A) and (B)].
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Figure 3.2. DGKζ KO mice are protected from papain-induced type 2 airway
inflammation. (A), Representative flow cytometry plots and enumeration of the
frequencies of WT and DGKζ KO lung ILC2 (pregated on CD45+Lin-CD90+ST2+ live
singlets with Lin- = CD3-CD5-CD11b-CD11c-CD19-B220-NK1.1-DX5-) expressing IL-5
and IL-13 following stimulation with media alone or PMA + ionomycin ex vivo (n = 9
mice/group). (B), Representative flow cytometry plots (pregated on CD45+Lin- live
singlets) of the frequencies and total cell numbers of BAL and lung ILC2 from WT or
DGK KO mice intranasally challenged with PBS or papain for 5 days (n = 9 mice/group).
(C), Representative flow cytometry plots and enumeration of the frequencies and total
numbers of WT and DGKζ KO lung ILC2 (pregated on CD45+Lin-CD90+ST2+ live
singlets) expressing Ki67 following intranasal challenge with PBS or papain for 5 days (n
= 3-5 mice/group). (D), Representative flow cytometry plots and enumeration of the
frequencies of WT and DGKζ KO lung ILC2 (pregated on CD45+Lin-CD90+ST2+ live
singlets) expressing IL-5 and IL-13 following restimulation with media alone or PMA +
ionomycin after intranasal challenge with papain for 5 days (n = 8 mice/group). (E), BAL
cytokine levels in PBS or papain-challenged WT and DGKζ KO mice (n = 6 mice/group).
(F), Representative flow cytometry plots (pregated on CD45+Ly6G- live singlets) of the
frequencies and total cell numbers of BAL and lung eosinophils from WT or DGK KO
mice intranasally challenged with PBS or papain for 5 days (n = 9 mice/group). Data are
pooled from at least 2 independent experiments (A, B, E, and F) or representative of 2
independent experiments (C-D). Data are represented as mean ± SEM; * P < 0.05, ** P
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< 0.01, *** P < 0.001, **** P < 0.0001, NS = not significant [One way ANOVA with
Tukey’s post-test, (A) through (F)].
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Figure 3.3. Protection from papain-induced airway inflammation in the absence of
DGKζ is not mediated by the hematopoietic compartment. (A), Representative flow
cytometry plots (pregated on CD45+Ly6G- live singlets) of the frequencies and total cell
numbers of BAL and lung eosinophils from Vav-Cre and Vav-Cre DGKζfl/fl mice
intranasally challenged with PBS or papain for 5 days (n = 5-13 mice/group). (B), Total
cell numbers of BAL and lung ILC2s (gated on CD45+Lin-CD90.2+ST2+ live singlets with
Lin- = CD3-CD5-CD11b-CD11c-CD19-B220-NK1.1-DX5-) from Vav-Cre or Vav-Cre
DGKζfl/fl mice intranasally challenged with PBS or papain for 5 days (n = 5-13
mice/group). (C), BAL cytokine levels in PBS or papain-challenged Vav-Cre or Vav-Cre
DGKζfl/fl mice (n = 2-3 mice/group for PBS challenged mice, n = 7-10 mice/group for
papain challenged mice). Data are pooled from at least 2 independent experiments and
represented as mean ± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, NS
= not significant [One way ANOVA with Tukey’s post-test, (A) and (B); two-sided
unpaired Student’s t-test, (C)].
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Figure 3.4. Airway inflammation driven by intranasal administration of IL-33 is
intact in DGKζ KO mice. (A), Representative flow cytometry plots (pregated on
CD45+Ly6G- live singlets) of the frequencies and total cell numbers of BAL and lung
eosinophils from WT, TSLPR KO, and ST2 KO mice intranasally challenged with PBS or
papain for 5 days (n = 3-4 mice/group). (B), Total cell numbers of BAL and lung ILC2s
(gated on CD45+Lin-CD90.2+CD25+ live singlets with Lin- = CD3-CD5-CD11b-CD11cCD19-B220-NK1.1-DX5-) from WT, TSLPR KO, and ST2 KO mice intranasally
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challenged with PBS or papain for 5 days (n = 3-4 mice/group). (C), BAL cytokine levels
in PBS or papain-challenged WT, TSLPR KO, and ST2 KO mice (n = 3-7 mice/group).
(D), Representative flow cytometry plots (pregated on CD45+Ly6G- live singlets) of the
frequencies and total cell numbers of eosinophils and (E), total cell numbers of ILC2
(gated on CD45+Lin-CD90.2+ST2+ live singlets) from the BAL and lungs of WT and DGKζ
KO mice intranasally challenged with PBS or IL-33 for 3 days (n = 5-6 mice/group for
PBS-challenged mice, n = 8-11 mice/group for IL-33-challenged mice). (F), BAL cytokine
levels in PBS or IL-33-challenged WT and DGKζ KO mice (n = 4-8 mice/group). Data are
representative of 2 independent experiments (A and B) or pooled from at least 2
independent experiments (B-F). Data are represented as mean ± SEM; * P < 0.05, ** P
< 0.01, *** P < 0.001, NS = not significant [One way ANOVA with Tukey’s post-test, (A)
through (F)].
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Figure 3.5. DGKζ KO lung ILC2s produce IL-5 and IL-13 in response to IL-33
stimulation normally. (A), IL-5 and IL-13 production from FACS-sorted WT and DGKζ
KO lung ILC2s stimulated with media alone, IL-2, IL-33, IL-2 + IL-33, or PMA +
ionomycin for 72 hours in vitro (n = 5 replicates, each replicate consisting of ILC2s
sorted from 5 pooled lungs). (B and C), Representative flow cytometry plots of in vitro
lung ILC2 (pregated on CD45.2+Lin-ST2+) expressing IL-5 and IL-13 following in vitro
expansion for 7 days followed by restimulation with media alone, IL-2, IL-33, IL-2 + IL33, or PMA + ionomycin for 4 hours. Data are pooled from 5 independent experiments
(A) or representative of 2 independent experiments (B-F). Data are represented as mean
± SEM; * P < 0.05, ** P < 0.01, *** P < 0.001, NS = not significant [One way ANOVA with
Tukey’s post-test, (A) through (F)].
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Figure 3.6. DGKζ KO mice display reduced IL-33 mRNA levels at homeostasis. (A),
IL33, IL25, Tslp mRNA expression in lung tissue of naïve WT and DGKζ KO mice.
Values shown were determined by RT-PCR and are normalized to Gapdh [n = 6
mice/group; done in collaboration with Li-Yin Hung]. (B), Representative flow cytometry
plots and enumeration of the frequencies of WT and DGKζ KO lung ILC2 (pregated on
CD45+Lin-CD90+ST2+ live singlets) expressing IL-5 following stimulation with media
alone or PMA + ionomycin ex vivo (n = 9 mice/group). Data are pooled from at least 2
independent experiments and represented as mean ± SEM; * P < 0.05, ** P < 0.01, *** P
< 0.001, **** P < 0.0001, NS = not significant [two-sided unpaired Student’s t-test, (A);
One way ANOVA with Tukey’s post-test, (B)].
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Figure 3.7. Loss of DGKζ in alveolar type II cells does not protect from papaininduced airway inflammation. (A), Representative flow cytometry plots (pregated on
CD45+Ly6G- live singlets) of the frequencies and total cell numbers of eosinophils and
(B) total cell numbers of ILC2s (gated on CD45+Lin-CD90.2+ST2+ live singlets with Lin- =
CD3-CD5-CD11b-CD11c-CD19-B220-NK1.1-DX5-) from the BAL and lungs of Nkx2.1-Cre
and Nkx2.1-Cre DGKζfl/fl mice intranasally challenged with PBS or papain for 5 days (n =
3-8 mice/group for PBS challenged mice, n = 7-11 mice/group for papain challenged
mice). (C), BAL cytokine levels in PBS or papain-challenged Nkx2.1-Cre and Nkx2.1-Cre
DGKζfl/fl mice (n = 3-6 mice/group for PBS challenged mice, n = 5-8 mice/group for
papain challenged mice). (D), Total cell numbers of eosinophils (gated on CD45.2+Ly6GCD11c-Siglec F+ live singlets) and ILC2s (gated on CD45+Lin-CD90.2+ST2+ live singlets)
in the BAL and lungs of Pirt-Cre and Pirt-Cre DGKζfl/fl or (E) Myh11-Cre, DGKζfl/fl, and
Myh11-Cre DGKζfl/fl mice intranasally challenged with PBS or papain for 5 days (n = 3-5
mice/group). Data are pooled from at least 2 independent experiments (A-C) or
representative of 1 independent experiment (D and E). Data are represented as mean ±
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SEM; NS = not significant [two-sided unpaired Student’s t-test, (A) through (D); One way
ANOVA with Tukey’s post-test, (E)].
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CHAPTER 4: DISCUSSION
Overview
This thesis aimed to further our understanding of how TCR-driven signal
transduction instructs Th2 differentiation of naïve CD4+ T cells. The notion that strong
TCR signaling blocks Th2 differentiation has existed since the late 1990’s, but the
majority of the previous studies demonstrating this phenomenon were carried out in vitro
using TCR transgenic T cells with single specificities and by modulating TCR signaling
either through altering TCR:peptide-MHC affinity or cognate peptide concentration. It
was unclear whether selective enhancement of specific TCR-mediated signal
transduction pathways could suppress Th2 differentiation in vitro and block Th2
inflammation in vivo in a polyclonal setting. Through genetic deletion of DGKζ, a
negative regulator of TCR signaling, we were able to demonstrate that enhancement of
DAG-mediated signaling could attenuate Th2 differentiation in vitro. Moreover, we were
able to show that this effect translated to protection against a Th2-mediated disease as
mice lacking DGKζ exhibited decreased type 2 airway inflammation in a mouse model of
allergic asthma. Further investigation of signaling pathways uncovered that the selective
enhancement of ERK signaling downstream of DAG was sufficient to inhibit Th2
differentiation and protect from Th2-mediated airway inflammation in vivo. This thesis is
the first to show that the specific enhancement of DAG signaling downstream of the TCR
is sufficient to attenuate Th2 differentiation and protect from Th2-mediated disease in an
ERK-dependent manner.
Additionally, through our studies, we uncovered that DGKζ plays an additional
role in regulating smooth muscle contraction and allergen-induced AHR independently of
its effects on airway inflammation. We observed that in addition to blunted type 2
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inflammation, mice lacking DGKζ were almost completely resistant to airway
hyperresponsiveness (AHR) in vivo in a mouse model of allergic asthma. A more
rigorous analysis revealed that the mechanisms by which DGKζ deficiency protected
against allergic asthma was more complex than originally hypothesized. Surprisingly, we
found that the mechanisms by which DGKζ protected against airway inflammation and
AHR were separable. Conditional deletion of DGKζ in T cells led to decreased type 2
airway inflammation with no attenuation of AHR. In contrast, conditional deletion of
DGKζ in airway smooth muscle cells led to diminished AHR with no attenuation of airway
inflammation. Furthermore, we found that loss of DGKζ diminished methacholineinduced tracheal smooth muscle contractile force generation, thus demonstrating that
DGKζ directly regulates smooth muscle contraction in a cell-intrinsic and inflammationindependent manner. Our findings reveal that the inflammatory and AHR components of
asthma are not as interdependent as generally believed and that DGKζ simultaneously
control both processes through distinct mechanisms.
Finally, we also demonstrate a novel role for DGKζ in regulating protease
allergen-mediated type 2 airway inflammation through the actions of DGKζ on the nonhematopoietic compartment. We find that genetic ablation of DGKζ was sufficient to
protect from papain-induced airway inflammation. However, the loss of DGKζ in the
hematopoietic compartment was not able to protect from airway inflammation following
papain treatment. Further analysis revealed that protection from papain in the absence
of DGKζ might potentially be due to an impairment in IL-33 production/release in
response to papain. However, further studies are needed to fully understand the
mechanism by which DGKζ influences protease allergen-driven type 2 immune
responses in the lung.
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Collectively, this thesis offers many novel findings and insights into the cell
signals that drive Th2 differentiation and allergic airway inflammation. Furthermore, we
demonstrate that enhancement of DAG signaling does not always lead to immune
activation, as generally believed. Additionally, this thesis highlights that DGKζ can also
play an immunomodulatory role in the non-hematopoietic compartment to regulate type
2 immune-mediated disease. The following sections discuss the implications of our
findings and further questions that remain from this work.
DAG-driven signal transduction blocks Th2 development
Several reports have indicated that strong and prolonged TCR signaling blocks
the differentiation of naïve CD4+ T cells into the Th2 lineage. By inhibiting various MAPK
pathways using small molecule inhibitors, the degree of TCR-mediated ERK activation
was determined to be a key regulator of this process (60). Through genetic deletion of a
negative regulator of DAG signaling or through knock-in of a hypersensitive ERK mutant,
we were able to demonstrate that selective enhancement of TCR-mediated ERK
signaling was sufficient to attenuate Th2 differentiation.
Strong TCR-mediated ERK signaling is thought to attenuate Th2 differentiation
by independently blocking early GATA3 induction and IL-2R-mediated STAT5 signaling
to impair early IL-4 transcription. However, the molecular nature by which TCR-mediated
ERK activity blocks these processes is not well understood. Jorritsma et al. have
suggested that strong TCR-mediated ERK signaling results in preferential skewing of Th
differentiation away from Th2 differentiation by altering ratio of AP-1 complexes from
predominantly JunB-JunB homodimers to JunB-cFos heterodimers following TCR
activation (58). However, Yamane et al. reported that activation of 5C.C7 TCR
transgenic T cells with low and high concentrations of pPCC (conditions that favor Th2
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and Th1 differentiation respectively) induced comparable levels of nuclear c-Fos
expression (60). Furthermore, activation of 5C.C7 T cells with high peptide
concentrations elicited higher expression of nuclear JunB expression at 24 hours
following TCR activation, thus arguing against altered ratios of AP-1 complexes as a
driver of differential early IL-4 production (60).
Additionally, further experiments will be needed to determine if the kinase activity
of ERK directly dampens IL-2R-mediated STAT5 phosphorylation. However, the role of
ERK in regulating STAT5 activity is controversial. Previous studies have shown that
ERK1/2 physically complexes with STAT5a in Chinese hamster ovary cells and that the
kinase activity of ERK1/2 is required for enhancement of STAT5a transcriptional activity
through phosphorylation of Ser780 on STAT5a (221). It is possible that the kinase
activity of ERK could also work upstream of STAT5 to dampen rather than promote IL2R-mediated STAT5 phosphorylation. Interestingly, TCR activation of naïve CD4+ T cells
has been shown to transiently inhibit phosphorylation and activation of multiple
components of the IL-4R signaling pathway, including IL-4Ra, Jak1, Jak3, STAT6, and
IRS-2, following ligation with IL-4 (222). TCR-mediated suppression of cytokine receptor
signaling was not limited to IL-4R signaling but also included IL-2R-mediated STAT5
activation, IL-6R-mediated signaling, and IFNa-mediated signaling (222). Importantly,
PLCg-dependent calcineurin and Ras-MAPK pathways were both involved in TCRmediated suppression of cytokine signaling in a manner that was independent of new
protein synthesis (222). Interestingly, inhibition of ERK activation using U0126 could
restore IL-4-mediated phosphorylation of STAT6 and IRS2 following TCR ligation,
suggesting that ERK activity is critical for regulating cytokine receptor responsiveness in
response to TCR stimulation (222). Furthermore, cytokine receptor responsiveness
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returned ~12 hours post TCR activation and became resistant to inhibition by
subsequent TCR ligation (222). However, inhibition of Th2 differentiation by strong and
prolonged TCR-mediated ERK signaling is likely not mediated by alterations in IL-4R
responsiveness because Th2 differentiation was restored in DGKz KO T cells following
addition of exogenous IL-4. However, it is possible that the strength of TCR-mediated
ERK signaling could delay the timing in which responsiveness of other cytokine
receptors (e.g. IL-2 receptor) is restored in order to drive preferential Th differentiation
toward a particular Th subset.
Moreover, the mechanism by which weak TCR-mediated signaling elicits early
GATA3 induction is also not very well understood. Previous work has shown that NF-kB
p50 subunit is required for GATA3 expression at late timepoints following TCR activation
under Th2 polarization conditions (223). However, the requirement for the NF-kB p50
subunit and other members of the NK-kB for early GATA3 expression and IL-4
transcription is unknown. Furthermore, the molecular mechanism by which strong TCRmediated ERK signaling blocks GATA3 mRNA induction is unknown. Our findings reveal
that augmenting TCR-mediated DAG signaling by genetic deletion of DGKζ is sufficient
to impair Th2 differentiation. The loss of DGKζ in T cells enhances both the NF-kB and
ERK signal transduction pathways following TCR activation. However, inhibition of ERK
signaling using U0126 was sufficient to restore Th2 differentiation in DGKζ, suggesting
that enhancement of TCR-mediated ERK signaling dominantly controls Th1 versus Th2
fate decision in DGKζ KO T cells. However, we do not know whether enhancement of
NF-kB signaling also contributes to this process. Analysis of the role of the NF-kB
pathway on Th differentiation has been hampered by the lack of mice with mutations in
components of the NF-kB pathway that lead to inducible augmentation of NF-kB
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signaling following TCR stimulation rather than constitutive activation of the pathway in
the absence of TCR signaling. However, further experiments will be needed using
inhibitors of the PKC-NF-kB pathway to determine if augmentation of the NF-kB pathway
also contributes to influencing Th2 differentiation in DGKζ KO T cells.
Regulation of airway hyperresponsiveness by DGK independent of eosinophilic
airway inflammation
Through our studies on the role of DGKζ on Th2 differentiation and allergeninduced airway inflammation, we uncovered that DGKζ also plays a critical role in airway
smooth muscle contraction and allergen-induced airway hyperresponsiveness. Allergic
asthma is a chronic airway inflammatory disease characterized by eosinophilic airway
inflammation and reversible airflow obstruction mediated in part by hypercontractility of
bronchial smooth muscle cells. The current paradigm argues that airway inflammation
drives the non-immune abnormalities observed in asthma. However, several reports
have hinted that the role of eosinophilic inflammation on the development of airway
hyperresponsiveness is more complex than originally thought. Systemic immunization
with OVA and aluminum hydroxide followed by intranasal challenge with OVA elicits
AHR in the airways of challenged mice in an IgE/mast-cell independent manner (224,
225). Cohn et al. demonstrated that transfer of IL-4 KO OVA-specific Th2 cells into naïve
WT recipient mice was sufficient to induce AHR despite markedly reduced airway
eosinophilia in comparison to transfer of WT OVA-specific Th2 cells, thus indicating that
IL-4 and eosinophils were not essential for the induction of OVA-induced AHR (160).
Furthermore, Corry et al. demonstrated that administration of neutralizing antibodies
against IL-4 or IL-5 during the effector phase had no impact on AHR induction despite
almost complete abrogation in OVA-induced eosinophilia, thus arguing that eosinophils
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are dispensable for allergen-induced AHR (163). These results likely reflect the
important role of IL-13 in OVA-induced AHR given that IL-13 KO mice exhibited
significantly impaired OVA-induced AHR despite intact OVA-induced airway eosinophilia
(226). However, it is important to note that that all of the previous studies were
performed in mice generated on the BALB/c background and that species-specific
differences in the mechanisms that regulate allergen-induced AHR do exist. In support of
this, Walsh et al. reported that eosinophil-deficient DdblGATA1 mice on the C57BL/6 but
not the BALB/c background displayed diminution in OVA-induced AHR, thus highlighting
that the factors that control OVA-induced airway disease can be different depending on
the species (227). Nevertheless, these results suggest that inflammation is important in
initiating the development of allergen-induced airway hyperresponsiveness.
Our findings add to this complexity by demonstrating that OVA-induced AHR can
develop normally even in the presence of diminished eosinophilia and Th2 cytokine
release in the airways. While the mechanism by which OVA-induced AHR is preserved
in hematopoietic-specific DGKζ KO mice might be due to retained IL-13 induction in the
BAL, the factors that explain why OVA-induced AHR remains intact despite attenuated
OVA-induced eosinophilic airway inflammation in DGKζ KO bone marrow chimeras and
ERKSEM mice are not entirely clear. One potential explanation is that the induction of
allergen-induced AHR is simply less sensitive to the reduction in type 2 cytokines than
the process of allergen-induced airway eosinophilia. However, an alternative explanation
could be that other T cell-derived factors, such as IL-3, could contribute to the induction
of OVA-induced AHR given that IL-3 KO mice display significantly attenuated OVAinduced AHR despite intact OVA-induced airway eosinophilia following OVA challenge
(228).
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Regardless of the inflammatory factors important in initiating OVA-induced AHR,
our studies indicate that DGKζ is essential for the development of AHR independently of
its role in regulating airway inflammation. However, the mechanism by which the loss of
DGKζ protects from allergen-induced AHR is not entirely clear. Previous studies have
shown that a rise in intracellular Ca2+ initiated by PLC critically mediates the crossbridge
cycling of actin and myosin to drive smooth muscle contraction and DAG maintains
contraction by inhibiting a negative regulator of the crossbridge cycling (191-193).
Consequently, one might expect that the lack of DGKζ would exacerbate
bronchoconstriction. However, the diminution of smooth muscle contraction by the loss
of DGKζ suggests that other biological mechanisms are involved. Indeed, preliminary
data from our collaborators indicate that inhibition of DGK kinase activity in human ASM
cells significantly impairs IP3 generation and Ca2+ flux following activation with
methacholine, thus resulting in decreased phosphorylation of myosin light chain and
decreased ASM contraction (data not shown). Exactly how the loss of DGKζ activity
leads to impaired methacholine-induced Ca2+responses is not fully understood but could
involve enhanced negative feedback of PKC isoforms on PLC activity, similar to what is
seen during FceRI-mediated activation of DGKζ KO mast cells (132).
Potential caveats of our results are that the deletion efficiencies of DGKζ in the
hematopoietic compartment in Vav-Cre DGKζfl/fl mice, in the T cell compartment in CD4Cre DGKζfl/fl mice, in airway smooth muscle cells in Myh11-Cre DGKζfl/fl mice, and in
dorsal root ganglion sensory neurons in the Pirt-Cre DGKζfl/fl mice are unknown.
Therefore, we cannot fully rule out the possibility that the phenotypes that we see in our
conditional DGKζ KO mice is due to DGKζ not being effectively deleted in these cell
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types. However, confirmation of the deletion efficiencies of DGKζ using our various Cre
systems are currently ongoing.
Importantly, our findings demonstrate that OVA-induced eosinophilic airway
inflammation and AHR are separable processes and that DGKζ is a common regulator
of both processes. Furthermore, these results suggest that while the initiation of the
molecular processes that lead to allergen-induced AHR might be inflammationdependent, the establishment of AHR is largely independent of eosinophilic
inflammation. In support of this, An et al. demonstrated that primary human airway
smooth muscle (ASM) cells isolated from asthmatic donors displayed significantly
enhanced baseline cell traction forces and augmented contraction in response to M3muscarinic receptor and H1-histamine receptor activation than non-asthmatic ASM cells
(229). These differences persisted even upon subsequent passaging of asthmatic ASM
cells, suggesting that the development of asthma generates cell-intrinsic changes in
airway smooth muscle cells to potentiate hypercontractile responses in an inflammationindependent manner (229). Moreover, recent clinical trials have shown that while
inhibition of type 2 cytokine signaling is efficacious in reducing eosinophilia and
decreasing the frequency of asthma exacerbations in asthmatic patients, these
approaches failed to alter impaired baseline lung function and histamine-induced airway
responses, thus implying that suppressing inflammation is not sufficient to reverse AHR
and airway smooth muscle dysfunction in asthma (194, 195). While the reasons for this
are not clear, it is tempting to speculate that the inflammation-independent nature of
airway smooth muscle dysfunction seen in asthmatic patients might be due to epigenetic
changes that occur in ASMs during the development of asthma that then drive
hyperactive responses to subsequent contractile triggers. While the current therapeutics
83

strategies have been focused on targeting the biological pathways that promote airway
inflammation, our data suggests that designing strategies to prevent and reverse airway
smooth muscle dysfunction, which is the core abnormality seen in both Th2-high and
Th2-low asthmatics, is equally as important. DGKζ potentially represents a novel
therapeutic target to promote the prevention and resolution of asthma by suppressing
both the immune and non-immune responses that drive the disease.
Regulation of protease-mediated airway inflammation by DGKζ
Through our studies, we identified that DGKζ also regulates type 2 airway
inflammation mediated by protease allergens, such as papain. However, the means by
which DGKζ protects from papain-induced airway inflammation is distinct in comparison
to the role of DGKζ in OVA-induced airway inflammation because DGKζ deficiency is
required in the non-hematopoietic compartment rather than the hematopoietic/T cell
compartments to elicit protection. The mechanism by which DGKζ controls papaininduced airway inflammation is not entirely clear but potentially revolves around the
regulation of IL-33, which is necessary for driving inflammation in the airways following
papain challenge. Surprisingly, DGKζ deficiency in alveolar type II cells, which comprise
the predominant source of pulmonary IL-33, was not sufficient to provide protection from
airway inflammation in response to papain. These data suggest that either DGKζ
regulates IL-33 production/release from alternative cellular sources to drive papaininduced inflammation in the lung or that DGKζ indirectly regulates IL-33
production/release from alveolar type II cells through another non-hematopoietic cell
type that is involved in sensing protease allergens and promoting IL-33 release from
alveolar type II cells. However, potential caveats of these results are that the deletion
efficiencies of DGKζ in the hematopoietic compartment in Vav-Cre DGKζfl/fl mice, in
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alveolar type II cells in Nkx2.1-Cre DGKζfl/fl mice, in airway smooth muscle cells in
Myh11-Cre DGKζfl/fl mice, and in dorsal root ganglion sensory neurons in the Pirt-Cre
DGKζfl/fl mice are unknown. Therefore, we cannot fully rule out the possibility that the
phenotypes that we see in our conditional DGKζ KO mice is due to DGKζ not being
effectively deleted in these cell types. However, confirmation of the deletion efficiencies
of DGKζ using our various Cre systems are currently ongoing.
While alveolar type II cells constitute a major source of IL-33, other lung cells,
such as CD31+ endothelial cells, PDGFRa-GFP+ adventitial stromal cells, EpCAM-CD31Sca1- stromal cells, and certain subsets of myeloid cells, also express IL-33 that could
be functionally relevant in regulating IL-33-mediated responses in the airways (220).
Indeed, Dahlgren et al. have shown that ILC2s reside around adventitial stromal cells
located in adventitial cuff structures present in the lung (220). Furthermore, adventitial
stromal cells express both IL-33 and TSLP to help support ILC2 maintenance in the lung
(220). In turn, ILC2-mediated production of IL-13 drives adventitial stromal cell
expansion and augments IL-33 expression (220). Depletion of adventitial stromal cells
during infection with Nippostrongylus brasiliensis impairs ILC2 and Th2 cell
accumulation and function in the lung partially in an IL-33-dependent manner, thus
suggesting that this adventitial stromal cell-ILC2 circuit is functionally relevant for
regulating ILC2 responses at homeostasis and during inflammation (220). However,
while the authors showed that ILC2s remain localized around adventitial cuff structures
following papain challenge, whether depletion of adventitial stromal cells or loss of
adventitial stromal cell-derived IL-33 impairs ILC2 responses during papain-mediated
lung inflammation was not addressed (220). Furthermore, the Cre-expressing mice that
we utilized for our studies (Nkx2.1-Cre, Pirt-Cre, and Myh11-Cre) likely do not display
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Cre activity in adventitial stromal cells and would not delete DGKζ in these cells upon
crossing these Cre-expressing mice to DGKζfl/fl mice. Further experiments involving the
generation of Gli-creERT2 DGKζfl/fl and Gli-creERT2 IL-33fl/fl mice to conditionally delete
DGKζ and IL-33 in adventitial stromal cells will be required to determine the role of DGKζ
and IL-33 in regulating papain-induced airway inflammation by adventitial stromal cells.
How the regulation of DAG-mediated signaling by DGKζ influences proteasemediated airway inflammation remains a mystery. However, DAG-driven signal
transduction pathways have been previously implicated in the regulation of tissuederived cytokines involved in type 2 inflammation. Deletion of IKKb, a catalytic subunit of
the IKK complex required for activation of the canonical NF-kB pathway, in intestinal
epithelial cells significantly diminished transcription of TSLP and impaired the induction
of protective type 2 immunity to Trichuris muris infection (230). In contrast, deletion of
IKKa, a catalytic subunit of the IKK complex involved in activation of both the canonical
and non-canonical NF-kB pathways, enhanced TSLP induction and impaired innate
immunity to Citrobacter rodentium infection by impairing IL-22 secretion from ILC3s
(231). While enhancing activation of the canonical NF-kB pathway by augmenting DAG
signaling would be expected to enhance TSLP transcription, it is possible that prolonged
DAG signaling can also inhibit the NF-kB pathway by downregulating components of the
canonical NF-kB pathway as seen in human colonic epithelial cells stimulated with PMA,
a DAG analogue resistant to DGK activity (232). Whether DAG signal transduction
pathways also influence IL-33 regulation is unknown. However, IL-33 has been shown to
upregulate DGKζ in cardiomyocytes but the functional relevance of this pathway and
whether this also occurs in airway cells exposed to IL-33 are not clear (85).
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It is also possible that DGKζ regulates the production and release of IL-33 by
regulating cell-death pathways. Protease allergens, such as papain, are thought to
promote cell damage to IL-33-expressing cells residing in the lung epithelium, resulting
in necrotic cell death and release of constitutively-produced IL-33 that is stored in the
nucleus of these cells (233). However, direct evidence that necrotic cell death drives the
release of IL-33 in response to protease allergens is lacking. Interestingly, we found that
RIPK3 KO mice, which cannot undergo programmed necroptosis, displayed intact
papain-induced ILC2 accumulation and eosinophilia in the lungs, thus ruling out a role
for programmed necroptotic cell death in IL-33 release (data not shown).
Additionally, it is also possible that the loss of DGKζ might promote protection
from papain-induced airway inflammation by altering the type of cell death that IL-33expressing cells undergo. Zhang et al. found that NLRP3 activating signals induce the
production of DAG to promote the recruitment of DAG effector molecule PKD (234). The
activity of PKD was critical for activation of NLRP3 inflammasome to cleave pro-caspase
1 to caspase-1 (234). In addition, we know that caspase-1 plays a regulatory role in IL33 biology by cleaving biologically active full-length IL-33 into biological inactive
fragments during inflammasome activation (235). In line with these results, caspase-1KO
and NLRP3 KO mice have been shown to display enhanced airway eosinophilia in
response to the protease allergen, HDM (236). The enhanced eosinophilic airway
inflammation was associated with increased IL-33 protein levels in lung at baseline and
following HDM treatment in caspase-1 KO mice, thus implying that NLRP3-mediated
activation of capase-1 is critical for dampening IL-33-mediated airway inflammation
following HDM challenge (236). However, we observed that DGKζ KO bone marrow
derived macrophages (BMDM) exhibited reduced NLRP3-mediated inflammasome
87

activation rather than enhanced activation (data not shown). Whether DGKζ deficiency
also dampens inflammasome activation in IL-33-expressing cells is not known but,
based on the BMDM data, we argue that the regulation of inflammasome activation to
control papain-induced release of bioactive IL-33 is not likely to be the mechanism by
which DGKζ protects from papain-induced airway inflammation. Further studies will need
to be done to determine how DGKζ acts to promote protease-mediated type 2 airway
inflammation in the non-hematopoietic compartment.
Broader implications of these pathways in sites outside of the lung
While these findings indicate that targeting DGKζ might be potentially beneficial
for the treatment of diseases that involve aberrant type 2 inflammation and pathological
smooth muscle function, DGKζ inhibition might also have detrimental effects in the lung
or other tissue compartments that require activation of these functions to protect the host
during infection or to maintain tissue homeostasis. For example, type 2 immune
responses are critical in protecting from helminth infections (237). In addition, smooth
muscle contraction in the gut is important for the expulsion of helminth parasites and
impairments in intestinal smooth muscle contraction have been shown to increase worm
burden (238-240). Therefore, the loss of DGKζ activity would be expected to impair
rather than promote host responses against helminths. Interestingly, smooth muscle
contraction is also important during childbirth (241). While global DGKζ KO female mice
can give birth and have relatively normal litter sizes, smooth muscle-specific DGKζ KO
females cannot give birth and die prior to delivery (unpublished results). These results
suggest that DGKζ might play a critical role in promoting delivery during parturition but
that compensatory factors also exist in regulating this process. It is tempting to speculate
that DGKζ might actually play a broader role in non-homeostatic contractile responses,
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such as those seen during AHR, intestinal smooth muscle-mediated helminth expulsion,
and uterine smooth muscle-mediated delivery of progeny during childbirth.
Conclusions
The work presented in this thesis describes how regulation of TCR-mediated
DAG signaling by DGKζ influences Th2 differentiation and Th2-mediated inflammation.
Through these studies, DGKζ was uncovered to a play a broader role in regulating
immune and non-immune responses associated with type 2 inflammation. Although Th2
differentiation has been studied extensively for decades, many questions still remain on
the key requirements for instructing the generation of this lineage. Further studies will be
needed to delineate the cellular and molecular pathways that are critical for the
development and function of Th2 cells and utilize this knowledge to control type 2
immune responses in clinical settings.

89

APPENDIX
Material and Methods

Chapter 2
Mice
C57BL/6, B6.SJL-PtprcaPepcb/BoyCrCrl (CD45.1+), and C57BL/6Tg(TcraTcrb)425Cbn/Crl (CD45.2+ WT OT-II) mice were purchased from The Jackson
Laboratories or Charles River Laboratories. Generation of DGKζ knockout (KO), DGKζ
floxed (DGKζfl/fl), and DGKα KO mice were described previously (170, 242, 243).
CD45.1+CD45.2+ WT OT-II mice were generated by crossing CD45.2+ WT OT-II to
CD45.1+ WT mice. CD45.2+ DGKζ KO mice were crossed to CD45.2+ WT OT-II mice to
generate CD45.2+ DGKζ KO OT-II mice. B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J (Vav-Cre) and
Tg(Cd4-cre)1Cwi/BfluJ (CD4-Cre) mice were purchased from the Jackson Laboratories
and crossed to DGKζfl/fl mice to generate Vav-Cre DGKζfl/fl and CD4-Cre DGKζfl/fl mice,
respectively. B6.Cg-Tg(Myh11-cre,-EGFP)2Mik/J (Myh11-Cre) mice were purchased
from The Jackson Laboratories and crossed to DGKζfl/fl mice to generate Myh11-Cre
DGKζfl/fl mice. Pirt-Cre mice were crossed to DGKζfl/fl mice to generate Pirt-Cre DGKζfl/fl
mice (244). IL-4 KO and STAT6 KO mice were purchased from The Jackson
Laboratories. Sevenmaker (ERKSEM) mice were provided by Laurence Samuelson from
the National Institutes of Health and were originally developed by Stephen Hedrick from
the University of California, San Diego (121). Unless otherwise specified, all mice were
7-12 weeks old at the time of use, were housed in pathogen-free conditions and treated
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in strict compliance with the Institutional Animal Care and Use Committee regulations at
the University of Pennsylvania.

Flow cytometry, cell sorting, and data analysis
For flow cytometric analyses, cells were stained with antibodies against cell surface
antigens at 4° C for 15 min in phosphate-buffered saline (PBS). LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit was used to exclude non-viable cells. Intracellular cytokine
staining was performed with the BD Cytofix/Cytoperm Kit according to the
manufacturer’s protocol. Flow cytometry was performed with a LSR II or FACSCanto
flow cytometer (BD Biosciences). For cell sorting, freshly isolated splenocytes were
stained with FITC-conjugated anti-CD4 (GK1.5, eBioscience) and anti-FITC MACS
beads (Miltenyi Biotec) and, subsequently, passed through MACS columns (Miltenyi
Biotec) according to the manufacturer’s protocol to enrich for CD4+ T cells. MACSenriched CD4+ T cells were subjected to cell surface staining prior to cell sorting. FACS
was performed with a FACSAria cell sorter (BD Biosciences). Data were analyzed and
plotted with FlowJo software (TreeStar). For flow cytometry, we utilized the following
fluorochrome-conjugated antibodies: BV605 anti-CD11b (M1/70, Biolegend), APC antiCD11c (N418, Tonbo Biosciences), unconjugated anti-CD16/CD32 (2.4G2, BD
Biosciences), PE Cy-7 anti-CD19 (eBio1D3, eBioscience), APC eF780 anti-CD25
(PC61.5, eBioscience), PE Cy7 anti-CD3 (17A2, Biolegend), FITC anti-mouse CD4
(RM4-5, eBioscience; GK1.5, eBioscience), PE anti-CD44 (IM7, eBioscience), APC Cy7
anti-CD45.1 (A20, BD Pharmingen), AF700 anti-CD45.2 (104, eBioscience), PE Cy7
anti-B220 (RA3-6B2, Biolegend), Pacific Blue anti-mouse CD45RB (C363-16A,
Biolegend), BV421 anti-F4/80 (BM8, Biolegend), PerCP eF710 anti-GATA3 (TWAJ,
eBioscience), PE Cy7 anti-IFNg (XMG1.2, Biolegend), PerCP eF710 anti-IL-13
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(eBio13A, eBioscience), BV711 anti-IL4 (11B11, Biolegend), APC anti-IL-5 (TRFK5,
Biolegend), PerCP Cy5.5 anti-Ly6G (HK1.4, Biolegend), PE anti-Siglec F (E50-2440, BD
Biosciences), FITC anti-Va2 (B20.1, BD Pharmingen), and PE anti-Vβ5.1, 5.2 (MR9-4,
BD Pharmingen). For western blots, we utilized the following antibodies: anti-pMLC (Ser
19) (3671, Cell Signaling Technologies), anti-pAkt (Ser473) (9271, Cell Signaling
Technologies), anti-MYPT1 (Thr696) (5163, Cell Signaling Technologies), and anti-αTubulin (DM1A) (3873, Cell Signaling Technologies).
CD4+ T cell differentiation assays
MACS-enriched CD4+ T cells were sorted for naïve T cells
(CD4+CD45RB+CD25−CD44lo). Sorted naïve CD4+ T cells were plated (30,000 cells/well)
in tissue culture media [MEMα (Invitrogen) with 10% heat-inactivated fetal bovine serum
(FBS; Atlanta Biologicals), penicillin (100 U/ml), streptomycin (100 μg/ml), 2 mM LGlutamine, 12.5 mM HEPES (Life Technologies), 22.9 μM β-mercaptoethanol (Bio-Rad)]
and activated with soluble anti-CD3 (10 μg/ml; 145-2C11; BD Pharmingen) and soluble
anti-CD28 (3 μg/ml; 37.51; BD Pharmingen) in the presence of irradiated (5000 rads)
CD4-depleted splenocytes (150,000 cells/well). In some experiments, sorted naïve CD4+
T cells were pretreated with either DMSO or the MEK1/2 inhibitor, U0126 (0.4 µM, Cell
Signaling), for 30 min prior to TCR activation. In other experiments, sorted naïve CD4+ T
cells were activated under TH2 conditions [anti-IL-12 (10 μg/ml; C15.6; Biolegend), antiIFNg (10 μg/ml; XMG1.2; Biolegend), IL-4 (10 ng/ml; Peprotech)]. On day 5 postactivation, T cells were restimulated with phorbol 12-myristate 13-acetate (PMA; 100
ng/ml; Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich) in the presence of
brefeldin A (5 μg/ml; Cell Signaling) for 5 hours. Following restimulation, activated T cells
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were washed twice with PBS and prepared for cell surface and intracellular cytokine
staining.

OVA-induced allergic asthma model
Mice were sensitized with an intraperitoneal (i.p.) injection of 10 μg OVA (Sigma-Aldrich)
and 2.25 mg of Imjectä Alum (ThermoFisher Scientific), which contains aluminum
hydroxide and magnesium hydroxide with inactive stabilizers, in 200 μl PBS on day 0
and day 14. Following sensitization, mice were intranasally (i.n.) challenged with 10 μg
OVA in 20 μl PBS on days 28-30. Airway responses to methacholine were measured
approximately 16 hours after the last i.n. challenge. Mice were anesthetized with an i.p
injection of ketamine (87.5 mg/kg, Hospira Inc.) and xylazene (12.5 mg/kg, Akorn Inc.),
cannulated via the trachea, and attached to a lung mechanics analyzer (FlexiVent,
SCIREQ Inc.). Airway responses were measured following the administration of
increasing doses of methacholine through the use of a nebulizer as we previously
described (245).
Following measurement of airway mechanics, the lung was flushed 3 times with
0.7 ml of MACS buffer [PBS with 5% bovine serum albumin (BSA; Fisher Bioreagents)
and 2 mM EDTA (Invitrogen)] containing complete Mini, EDTA-free protease inhibitor
cocktail (Roche). The BAL fluid was centrifuged at 6797 x g at 4° C for 2 min in a
microcentrifuge. BAL supernatant was collected and stored at -80° C prior to analysis.
For measurement of cytokine concentrations in cell-free BAL fluid, mouse-specific IL-4
(BD Biosciences), IL-5 (Biolegend), and IL-13 (eBioscience) ELISA kits were used
according to the manufacturer’s protocol. The remaining BAL cell pellet was treated with
erythrocyte lysis buffer (ELB), pelleted, and resuspended in PBS for analysis by cytospin
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or flow cytometry. For cytospin analysis, BAL cells were spun down onto cytospin slides
using a cytocentrifuge. Slides were air dried and stained with Shandon Kwik-Diff
(ThermoFisher Scientific) according to the manufacturer’s protocol. Differential BAL cell
counts were performed manually with at least 200 total cells counted for each slide as
previously described (246-248). For analysis by flow cytometry, BAL cells were stained
with antibodies against cell surface markers and identified by the following gating
schemes: eosinophils (Ly6G-CD11c-Siglec F+), neutrophils (CD11b+Ly6G+),
macrophages (Ly6G-F4/80+), and lymphocytes (CD3+ or CD19+ or B220+). All cells were
pregated on CD45+ live cells.
Following BAL fluid collection, murine lungs were injected with 10% buffered
formalin (Fisher Healthcare) though the trachea, harvested, and incubated in 10%
buffered formalin overnight to allow for fixation. Next, lung tissue was dehydrated,
paraffin-embedded, and sliced into sections. Tissue sections were stained with
hematoxylin and eosin (H&E) to determine cellular infiltrates in the lung (249, 250).
Inflammation was scored by two blinded investigators on a scale of 0 (no tissue
inflammation) to 5 (severe inflammation with involvement of the peribronchial,
perivascular and parenchymal regions.

Adoptive transfer of WT and DGKζ KO OT-II
MACS-enriched CD4+ T cells isolated from spleens and lymph nodes of
CD45.1+CD45.2+ WT OT-II TCR transgenic mice and CD45.2+ DGKζ KO OT-II TCR
transgenic mice were sorted for naïve T cells (CD4+CD45RB+CD25−CD44lo). Sorted
naïve CD45.1+CD45.2+ WT OT-II and CD45.2+ DGKζ KO OT-II cells were transferred
intravenously into CD45.1+ WT hosts at a 1:1 ratio (400,000 WT OT-II:400,000 DGKζ
OT-II). One day post-transfer, mice were subjected to OVA sensitization. Five days after
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the second i.p. OVA/Alum immunization, splenic CD4+ T cells were isolated via MACSenrichment and restimulated with phorbol 12-myristate 13-acetate (PMA; 100 ng/ml;
Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich) in the presence of brefeldin A (5
μg/ml; Cell Signaling) for 5 hours. Following restimulation, activated CD4+ T cells were
washed twice with PBS and prepared for cell surface and intracellular cytokine staining.

Generation of bone marrow chimeric mice
Donor bone marrow (BM) cells from CD45.1+ WT or CD45.2+ DGKζ KO donor mice were
transferred (3-4 x 106 BM cells) intravenously into lethally irradiated (1100 rads) CD45.1+
WT or CD45.2+ DGKζ KO hosts. 10 weeks post-bone marrow transfer, mice were
subjected to OVA sensitization and challenge.

Murine tracheal ring contraction
Airway contractility in isolated murine tracheal rings was determined using multi-wire
myograph (ADInstruments) as described previously (251). Tracheal rings were mounted
on the myograph, bathed in Krebs-Henseleit (K-H) buffer (pH 7.4, 37°C and 95% O2/5%
CO2), and baseline tension was set at ~2.5 mN. After the rings attained a stable baseline
tension, airways were challenged with increasing concentrations of methacholine and
the change in tension was recorded. At the end of the last dose of methacholine, the
airways were washed with K-H buffer. Data acquisition and analysis was performed
using Chart 7 software.

Airway contraction measurements in human precision cut lung slices (PCLS)
Human PCLS preparation and bronchoconstriction experiments were performed as
previously described (252). In brief, healthy whole lungs from non-asthmatic donors
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were received from the National Disease Research Interchange (Philadelphia, PA).
Lungs were inflated with 2% low melting temperature agarose, sectioned, cored (8 mm
diameter), and sliced at a thickness of 350 μm (Precisionary Instruments VF300
Vibratome). Lung slices were rested in Ham’s F12 medium in 12-well tissue culture
plates at 37° C for two days post-isolation and washed three times with fresh media to
rid airways of agarose on day 1 and 2 during the resting period. Next, slices were
incubated overnight (18 hours) with DMSO or DGK inhibitor, R59949 (Sigma-Aldrich).
Following overnight incubation, slices were challenged with increasing doses of
carbachol (Sigma-Aldrich) and live video images of the airways were taken after each
dose using a microscope (Nikon Eclipse TE2000-U, 40x magnification) connected to a
live video feed (Evolution QEi 32-0074A-130). Suitable airways on slices were chosen
based on the following criteria: presence of a full smooth muscle wall, intact beating cilia,
and absence of shared muscle walls at airway branch points to exclude possible
counteracting contractile forces. Changes in airway lumenal area were measured using
Image-Pro Plus software (version 6.0, Media Cybernetics) as previously described (252).
Area under curve (AUC) was calculated from the dose-response curves generated.

Human airway smooth muscle (HASM) isolation, culture, and immunoblotting
Primary HASM were generated from non-diseased tracheas received from the National
Disease Research Interchange (Philadelphia, PA). HASM culture was performed as
previously described (253). HASM cells were cultured in Ham’s F12 medium
supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (0.1 mg/ml) and
amphotericin B (2.5 mg/ml) for up to 1-5 passages prior to use.
For immunoblotting analysis, HASM cells were grown to confluence in 12 well
tissue culture plates. Cells were serum starved for 24 hours prior to stimulation. Cells
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were incubated overnight (18 hours) with DMSO or R59949. Following overnight
incubation, cells were stimulated with 10 μM carbachol for 10 min. After stimulation, cells
were fixed with perchloric acid, scraped, pelleted, and lysed in RIPA buffer. Lysates
were subjected to SDS-PAGE and transferred to nitrocellulose membranes.
Immunoblotting for phosphorylated myosin light chain (pMLC), phospho-Akt (pAkt), and
phosphorylated myosin light chain phosphatase (pMYPT1) was performed using tubulin
as a loading control. The antibodies used for immunoblotting are listed in Supplemental
Table 2.

In vivo systemic administration of DGK inhibitor
For pharmacological inhibition of DGK activity in vivo, mice were intraperitoneally
injected once daily with either DMSO or 10 mg/kg of DGK inhibitor, R59949 (SigmaAldrich), in 50% polyethylene glycol (PEG) 400 (Sigma-Aldrich) solution beginning
immediately after the second i.p. OVA/Alum immunization and ending before the last i.n.
OVA challenge (late sensitization and challenge phases) or beginning immediately
before the first i.n. OVA challenge and ending before the last i.n. OVA challenge
(challenge phase only).

Statistical analysis
P values were calculated using unpaired or paired two-tailed Student’s t-test, one-way
ANOVA with Tukey’s post-test or Dunn’s post-test analysis, or two-way ANOVA with
Bonferroni’s post-test analysis as indicated in the figure legends. Graphical
representation and statistical analysis of data were performed with Prism 6 software
(GraphPad).
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Chapter 3

Mice
C57BL/6 were purchased from Charles River Laboratories. Generation of DGKζ
knockout (KO) and DGKζ floxed (DGKζfl/fl) were described previously (170, 242, 243).
B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J (Vav-Cre) were purchased from the Jackson
Laboratories and crossed to DGKζfl/fl mice to generate Vav-Cre DGKζfl/fl. C57BL/6JTg(Nkx2-1-cre)2Sand/J (Nkx2.1-Cre) mice were purchased from The Jackson
Laboratories and crossed to DGKζfl/fl mice to generate Nkx2.1-Cre DGKζfl/fl mice. B6.CgTg(Myh11-cre,-EGFP)2Mik/J (Myh11-Cre) mice were purchased from The Jackson
Laboratories and crossed to DGKζfl/fl mice to generate Myh11-Cre DGKζfl/fl mice. Pirt-Cre
mice were crossed to DGKζfl/fl mice to generate Pirt-Cre DGKζfl/fl mice (244). TSLPR KO
mice were provided by Warren Leonard from the National Institutes of Health (254).
Il1rl1−/− mice (ST2 KO) were provided by Edward Behrens from the University of
Pennsylvania and were originally developed by Andrew McKenzie at the University of
Cambridge (199). Unless otherwise specified, all mice were 7-12 weeks old at the time
of use, were housed in pathogen-free conditions and treated in strict compliance with the
Institutional Animal Care and Use Committee regulations at the University of
Pennsylvania.

Flow cytometry, cell sorting, and data analysis
For flow cytometric analyses, cells were stained with antibodies against cell surface
antigens at 4° C for 15 min in phosphate-buffered saline (PBS). LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit was used to exclude non-viable cells. Intracellular cytokine
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staining was performed with the BD Cytofix/Cytoperm Kit according to the
manufacturer’s protocol. Intracellular transcription factor staining was performed with the
eBioscience™ Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher Scientific)
according to manufacturer’s protocol. Flow cytometry was performed with a LSR II or
FACSCanto flow cytometer (BD Biosciences). For cell sorting, freshly isolated cells from
lung tissue were subjected to cell surface staining prior to cell sorting. FACS was
performed with a FACSAria cell sorter (BD Biosciences). Data were analyzed and
plotted with FlowJo software (TreeStar). For flow cytometry, we utilized the following
fluorochrome-conjugated antibodies: PerCP Cy5.5 anti-Ly6G (HK1.4, Biolegend), APC
anti-CD11c (N418, Tonbo Biosciences), AF700 anti-CD45.2 (104, eBioscience), PE antiSiglec F (E50-2440, BD Biosciences), BV421 anti-F4/80 (BM8, Biolegend), BV605 antiCD11b (M1/70, Biolegend), PE anti-CD25 (PC61, Biolegend), PE Cy7 anti-CD3 (17A2,
Biolegend), PE Cy7 anti-CD5 (53-7.3, eBioscience), PE Cy7 anti-mouse CD11b (M1/70,
Biolegend), PE Cy7 anti-mouse CD11c (N418, Biolegend), PE Cy-7 anti-CD19
(eBio1D3, eBioscience), PE Cy7 anti-B220 (RA3-6B2, Biolegend), PE Cy7 anti-NK1.1
(PK136, Biolegend), PE Cy7 anti-CD49b (DX5, Biolegend), APC eF780 anti-CD90.2 (532.1, eBioscience), PE anti-CD127 (A7R34, Tonbo Biosciences), biotinylated anti-ST2
(DJ8, MD Biosciences), PE Cy7 anti-IFNg (XMG1.2, Biolegend), PerCP eF710 anti-IL-13
(eBio13A, eBioscience), BV711 anti-IL4 (11B11, Biolegend), APC anti-IL-5 (TRFK5,
Biolegend), PerCP Cy5.5 anti-Ly6G (HK1.4, Biolegend), unconjugated anti-CD16/CD32
(2.4G2, BD Biosciences). PerCP eF710 anti-GATA3 (TWAJ, eBioscience), PerCP
eF710 anti-Ki67 (SolA15, eBioscience), and BV421 Streptavidin (405225).
Papain-induced allergic airway inflammation model
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For induction of acute type 2 airway inflammation, mice were intranasally (i.n.)
challenged with either 20 μl PBS alone or 30 μg papain (Calbiochem) in 20 μl PBS daily
for 5 days, and euthanized on day 6 for analysis.

Intranasal treatment with IL-33

For induction of acute IL-33-mediated inflammation., mice were intranasally (i.n.)
challenged with either 20 μl PBS alone or 200 ng IL-33 (Peprotech) in 20 μl PBS daily
for 3 days, and euthanized on day 4 for analysis.

Isolation of cells from the BAL and lung tissue

Following euthanasia, mice were cannulated via the trachea and the lung was flushed
once with 0.7 ml of MACS buffer [PBS with 5% bovine serum albumin (BSA; Fisher
Bioreagents) and 2 mM EDTA (Invitrogen)] containing complete Mini, EDTA-free
protease inhibitor cocktail (Roche). The BAL fluid was centrifuged at 6797 x g at 4° C for
2 min in a microcentrifuge. BAL supernatant was collected and stored at -80° C prior to
analysis. The remaining BAL cell pellet was treated with erythrocyte lysis buffer (ELB),
pelleted, and resuspended in PBS for analysis by flow cytometry.
For isolation of cells from lung tissue, lungs were perfused with 5 ml of PBS
through the right ventricle of the heart prior to removal. Lung lobes were cut into small
pieces with scissors and digested with 0.1 Wünsch units/ml of Liberase TM (Roche) and
25 μg/ml of DNase I (Roche) in 5 ml of 1x Hank’s Balance Salt Solution (HBSS) with
Ca2+ and Mg2+ (Corning) for 1 hour at 37° C on a mechanical shaker (180 rpm). Samples
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were passed through 70-μm Nylon filter paper, pelleted, and treated with ELB buffer.
Cells were washed and resuspended in PBS for analysis by flow cytometry.

Detection of BAL cytokines
For measurement of cytokine concentrations in cell-free BAL fluid, mouse-specific IL-4
(BD Biosciences), IL-5 (Biolegend), and IL-13 (eBioscience) ELISA kits were used
according to the manufacturer’s protocol.

ILC2 restimulation, isolation, and in vitro expansion
For detection of cytokine-production from ILC2s from naïve, PBS, or papainchallenged mice, single-cell suspensions of cell isolated from lung tissue were
resuspended in tissue culture media [MEMα (Invitrogen) with 10% heat-inactivated fetal
bovine serum (FBS; Atlanta Biologicals), penicillin (100 U/ml), streptomycin (100 μg/ml),
2 mM L-Glutamine, 12.5 mM HEPES (Life Technologies), 22.9 μM β-mercaptoethanol
(Bio-Rad)], plated in 96 well-plates, and stimulated with either media alone or with
phorbol 12-myristate 13-acetate (PMA; 100 ng/ml; Sigma-Aldrich) and ionomycin (1
μg/ml; Sigma-Aldrich) in the presence of brefeldin A (5 μg/ml; Cell Signaling) for 4 hours.
Following stimulation, activated lung cells were washed twice with PBS and prepared for
cell surface and intracellular cytokine staining.
For ILC2 isolation, lung cells were pooled at least 5 mice per group and lung
ILC2s were FACS-sorted from the lineage-negative (CD3-CD5-CD11b-CD11c-CD19B220-NK1.1-DX5-) CD90+ST2+ population. Sorted ILC2s were resuspended in tissue
culture media and plated at a density of 10,000 cells/well in 96-well plates. ILC2 were
stimulated with media alone, IL-2 (1000 U/ml; Peprotech), IL-33 (10 ng/ml; Peprotech),
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or PMA (100 ng/ml; Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich) for 72 hours.
Cell-free supernatant were collected and analyzed for IL-5 and IL-13 cytokines by
ELISA.
For in vitro expansion, FACS-sorted lung ILC2s were resuspended in tissue
culture media and plated at a density of 10,000 cells/well in 96-well plates. ILC2 were
expanded with IL-2 (1000 U/ml; Peprotech) and IL-33 (10 ng/ml; Peprotech) for 5 days.
Expanded ILC2 were then washed, replated, and rested in IL-2 (1000 U/ml; Peprotech)
for 2 days. Following resting, expanded ILC2s were washed, plated (50,000 cells/well),
and restimulated with media alone, IL-2 (1000 U/ml; Peprotech), IL-33 (10 ng/ml;
Peprotech), or PMA (100 ng/ml; Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich)
in the presence of brefeldin A (5 μg/ml; Cell Signaling) for 4 hours. Following
restimulation, activated ILC2s were washed twice with PBS and prepared for cell surface
and intracellular cytokine staining.

Quantitative Real-Time PCR
Total RNA was harvested from lung or intestinal tissues with the use of RNeasy Mini kit
(Qiagen, Hilden, Germany) according to the manufacturer's protocol. Total RNA (500 ng)
was reverse-transcribed with Superscript II (Invitrogen, Carlsbad, CA) according to the
manufacturer's protocol. One to four diluted cDNA samples were added to
SsoAdavanced SYBR Green Supermix (Bio-Rad, Hercules, CA), and real-time PCR
reactions were run on CFX96 Real-Time PCR detection system (Bio-Rad). Gene
expression is normalized to Gapdh, and data are presented as means ± SEM from the
replicates. Primers used in this study included the following: Gapdh forward: 5′AGGTCGGTGTGAACGGATTTG-3′, and reverse: 5′TGTAGACCATGTAGTTGAGGTCA-3′; Il25 forward: 5′102

GCTGTTGCTGAAGAAGGTAGT-3′, and reverse: 5′-TTCAAGTCCCTGTCCAAC3′; Il33 forward: 5′-TCCCAACAGAAGACCAAAG-3′, and reverse: 5′-GATACTGCCAAGCAAGGAT-3′;

Statistical analysis
P values were calculated using unpaired two-tailed Student’s t-test or one-way ANOVA
with Tukey’s post-test as indicated in the figure legends. Graphical representation and
statistical analysis of data were performed with Prism 6 software (GraphPad).
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